<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">63429</article-id><article-id pub-id-type="doi">10.7554/eLife.63429</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Structural basis for human TRPC5 channel inhibition by two distinct inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-209349"><name><surname>Song</surname><given-names>Kangcheng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7932-2202</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-209350"><name><surname>Wei</surname><given-names>Miao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6304-4778</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209351"><name><surname>Guo</surname><given-names>Wenjun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228058"><name><surname>Quan</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104741"><name><surname>Kang</surname><given-names>Yunlu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104629"><name><surname>Wu</surname><given-names>Jing-Xiang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9851-0065</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-104151"><name><surname>Chen</surname><given-names>Lei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7619-8311</contrib-id><email>chenlei2016@pku.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>State Key Laboratory of Membrane Biology, College of Future Technology, Institute of Molecular Medicine, Beijing Key Laboratory of Cardiometabolic Molecular Medicine, Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>Peking-Tsinghua Center for Life Sciences, Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>Academy for Advanced Interdisciplinary Studies, Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Stockbridge</surname><given-names>Randy B</given-names></name><role>Reviewing Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Aldrich</surname><given-names>Richard W</given-names></name><role>Senior Editor</role><aff><institution>The University of Texas at Austin</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>03</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e63429</elocation-id><history><date date-type="received" iso-8601-date="2020-09-24"><day>24</day><month>09</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-03-05"><day>05</day><month>03</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Song et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Song et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-63429-v2.pdf"/><abstract><p>TRPC5 channel is a nonselective cation channel that participates in diverse physiological processes. TRPC5 inhibitors show promise in the treatment of anxiety disorder, depression, and kidney disease. However, the binding sites and inhibitory mechanism of TRPC5 inhibitors remain elusive. Here, we present the cryo-EM structures of human TRPC5 in complex with two distinct inhibitors, namely clemizole and HC-070, to the resolution of 2.7 Å. The structures reveal that clemizole binds inside the voltage sensor-like domain of each subunit. In contrast, HC-070 is wedged between adjacent subunits and replaces the glycerol group of a putative diacylglycerol molecule near the extracellular side. Moreover, we found mutations in the inhibitor binding pockets altered the potency of inhibitors. These structures suggest that both clemizole and HC-070 exert the inhibitory functions by stabilizing the ion channel in a nonconductive closed state. These results pave the way for further design and optimization of inhibitors targeting human TRPC5.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>TRPC5</kwd><kwd>clemizole</kwd><kwd>HC-070</kwd><kwd>TRPC</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2016YFA0502004</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>91957201</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31900859</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Jing-Xiang</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2016M600856</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Jing-Xiang</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2017T100014</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Jing-Xiang</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2019M650324</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Jing-Xiang</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2019T120014</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Jing-Xiang</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31870833</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31821091</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The binding sites of two distinct TRPC5 inhibitors clemizole and HC-070 are revealed by cryo-EM.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The mammalian transient receptor potential canonical (TRPC) channels are Ca<sup>2+</sup>-permeable nonselective cation channels that belong to the transient receptor potential (TRP) channel superfamily (<xref ref-type="bibr" rid="bib13">Clapham, 2003</xref>). Among all the subfamilies of TRP channels, TRPC channels share the closest homology to the <italic>Drosophila</italic> TRP channel, the first TRP channel cloned (<xref ref-type="bibr" rid="bib31">Montell and Rubin, 1989</xref>). The TRPC subfamily is formed by seven channels in mammals, TRPC1-TRPC7, while TRPC2 is a pseudogene in human. According to the primary amino acid sequences, TRPC channels can be divided into TRPC1, TRPC2, TRPC3/6/7, and TRPC4/5 subgroups (<xref ref-type="bibr" rid="bib30">Montell et al., 2002</xref>). Among them, TRPC5 is mainly expressed in the brain and to a lesser extent in the liver, kidney, testis, and pancreas (<xref ref-type="bibr" rid="bib35">Philipp et al., 1998</xref>; <xref ref-type="bibr" rid="bib45">Sossey-Alaoui et al., 1999</xref>; <xref ref-type="bibr" rid="bib49">Uhlén et al., 2015</xref>). It can form homotetrameric channels or heterotetrameric channels with TRPC4 and/or TRPC1 (<xref ref-type="bibr" rid="bib12">Chung et al., 2007</xref>; <xref ref-type="bibr" rid="bib11">Chung et al., 2006</xref>). TRPC5 activation leads to the depolarization of cell membrane and an increase of intracellular Ca<sup>2+</sup> level ([Ca<sup>2+</sup>]<sub>i</sub>). TRPC5 mediates diverse physiological processes and is implicated in many disease conditions in human such as fear, anxiety, depression, and progressive kidney disease (<xref ref-type="bibr" rid="bib38">Riccio et al., 2009</xref>; <xref ref-type="bibr" rid="bib41">Schaldecker et al., 2013</xref>).</p><p>TRPC5 channel is regulated by several physiological mechanisms, including cell surface receptors, calcium stores, redox status, and calcium. TRPC5 can be activated by receptor-activated G<sub>q/11</sub>-PLC pathway upon the dissociation of Na<sup>+</sup>/H<sup>+</sup> exchanger regulatory factor and activation of IP<sub>3</sub> receptors (<xref ref-type="bibr" rid="bib23">Kanki et al., 2001</xref>; <xref ref-type="bibr" rid="bib40">Schaefer et al., 2000</xref>; <xref ref-type="bibr" rid="bib46">Storch et al., 2017</xref>), or through the G<sub>i/o</sub> pathway (<xref ref-type="bibr" rid="bib21">Jeon et al., 2012</xref>). By interacting with STIM1, TRPC5 functions as a store-operated channel (<xref ref-type="bibr" rid="bib3">Asanov et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Zeng et al., 2004</xref>). Extracellular application of reduced thioredoxin or reducing agents enhances TRPC5 activity (<xref ref-type="bibr" rid="bib54">Xu et al., 2008</xref>). TRPC5 is also regulated by [Ca<sup>2+</sup>]<sub>i</sub> in a concentration-dependent bell-shaped manner (<xref ref-type="bibr" rid="bib7">Blair et al., 2009</xref>; <xref ref-type="bibr" rid="bib19">Gross et al., 2009</xref>; <xref ref-type="bibr" rid="bib33">Ordaz et al., 2005</xref>; <xref ref-type="bibr" rid="bib57">Zeng et al., 2004</xref>), and extracellular Ca<sup>2+</sup> ([Ca<sup>2+</sup>]<sub>o</sub>) at concentration higher than 5 mM robustly activates TRPC5 (<xref ref-type="bibr" rid="bib40">Schaefer et al., 2000</xref>; <xref ref-type="bibr" rid="bib57">Zeng et al., 2004</xref>).</p><p>Several available pharmacological tool compounds permit the identification of TRPC5 as putative drug targets for several diseases in human (<xref ref-type="bibr" rid="bib27">Minard et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Sharma and Hopkins, 2019</xref>; <xref ref-type="bibr" rid="bib51">Wang et al., 2020</xref>). (-)-Englerin A (EA), a natural product obtained from <italic>Phyllanthus engleri</italic>, can selectively activate TRPC4/5 and therefore inhibit tumor growth (<xref ref-type="bibr" rid="bib2">Akbulut et al., 2015</xref>; <xref ref-type="bibr" rid="bib9">Carson et al., 2015</xref>), suggesting activation of TRPC4/5 might be a strategy to cure certain types of cancer. Moreover, TRPC5 inhibitors showed promising results for the treatment of central nervous system diseases and focal segmental glomerulosclerosis in animal models (<xref ref-type="bibr" rid="bib22">Just et al., 2018</xref>; <xref ref-type="bibr" rid="bib55">Yang et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Zhou et al., 2017</xref>). A TRPC4/5 inhibitor developed by Hydra and Boehringer Ingelheim is currently in clinical trial for the treatment of anxiety disorder and depression (<xref ref-type="bibr" rid="bib53">Wulff et al., 2019</xref>). Another TRPC5 inhibitor GFB-887 developed by Goldfinch Bio is in phase 1 clinical trial for the treatment of kidney disease (NCT number: NCT03970122).</p><p>Among TRPC5 inhibitors, clemizole (CMZ) and HC-070 represent two distinct classes in terms of chemical structures. CMZ is a benzimidazole-derived H1 antagonist that can inhibit TRPC5. M084 and AC1903 are also TRPC5 inhibitors that belong to the CMZ class (<xref ref-type="bibr" rid="bib39">Richter et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Zhou et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Zhu et al., 2015</xref>). In contrast, HC-070 is a methylxanthine derivative that inhibits TRPC4/5 with high potency (<xref ref-type="bibr" rid="bib22">Just et al., 2018</xref>). TRPC5 inhibitor Pico145 (HC-608) and activator AM237 belong to this class (<xref ref-type="bibr" rid="bib22">Just et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Minard et al., 2019</xref>). The distinct sizes, shapes, and chemical characteristics between CMZ and HC-070 type inhibitors suggest that they bind human TRPC5 (hTRPC5) at different sites. However, these sites remain enigmatic due to the lack of reliable structural information, which greatly impedes further structure-based compound optimizations. To understand the binding and inhibitory mechanism of these two types of inhibitors, we embarked on structural studies of hTRPC5 in complex with CMZ or HC-070.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Structure of hTRPC5 in apo state and in complex with inhibitors</title><p>We show that extracellular calcium and EA can robustly elevate intracellular calcium concentration through hTRPC5 channel activation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–C</xref>), as reported previously (<xref ref-type="bibr" rid="bib22">Just et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Schaefer et al., 2000</xref>; <xref ref-type="bibr" rid="bib57">Zeng et al., 2004</xref>). Moreover, CMZ and HC-070 effectively inhibited the extracellular calcium-induced intracellular calcium increase in a dose-dependent manner (<xref ref-type="fig" rid="fig1">Figure 1A–B</xref>). To reveal the binding sites of EA, CMZ, and HC-070 on hTRPC5, we expressed hTRPC5 in HEK293F cells for structural studies. It is previously reported that the C-terminal truncation of mTRPC increased expression level and retained its pharmacology profile (<xref ref-type="bibr" rid="bib16">Duan et al., 2019</xref>). Similarly, we found the C-terminal truncation of hTRPC5 yielded a construct (hTRPC5<sub>1-764</sub>) that can be activated by EA and extracellular calcium and can be inhibited by HC-070 and CMZ (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–C</xref>). This construct showed a higher expression level of the tetrameric channel in comparison with the full-length wild-type (WT) hTRPC5 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Therefore, we used hTRPC5<sub>1-764</sub> protein for structural studies. Tetrameric hTRPC5<sub>1-764</sub> channel was purified in detergent micelles (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E–F</xref>). To obtain the EA-bound, CMZ-bound, and the HC-070-bound TRPC5 structures, we added EA, CMZ, or HC-070 to the protein for cryo-EM sample preparation. For the cryo-EM sample in the presence of EA, we obtained a reconstruction at the resolution of 3.0 Å (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplements 2</xref>–<xref ref-type="fig" rid="fig1s3">3</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Unfortunately, we could not locate the density of EA, indicating EA was not bound on the protein, probably due to reduced affinity of EA toward purified TRPC5 protein in the current condition. Therefore, we refer this structure as the ‘apo’ state of hTRPC5, which closely resembles previously published ‘apo’ mouse TRPC5 structure (PDB ID: 6AEI) (<xref ref-type="bibr" rid="bib16">Duan et al., 2019</xref>) with root-mean-square deviation (RMSD) of 1.844 Å. In addition, we obtained maps of hTRPC5 in CMZ-bound state and HC-070-bound state to the resolution of 2.7 and 2.7 Å, respectively (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplements 4</xref>–<xref ref-type="fig" rid="fig1s7">7</xref>, <xref ref-type="table" rid="table1">Table 1</xref>), which unambiguously revealed the ligand densities of CMZ and HC-070 described as below (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5E–F</xref>, <xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7E–F</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Overall structure of human TRPC5 (hTRPC5).</title><p>(<bold>A, B</bold>) Inhibitory effect of clemizole (CMZ) (<bold>A</bold>) and HC-070 (<bold>B</bold>) on the extracellular calcium-induced intracellular calcium increase of cells with wild-type hTRPC5 over-expression measured by FLIPR calcium assay (data are shown as means ± standard error, n = 3 independent experiments). (<bold>C, D</bold>) Cryo-EM density maps of CMZ-bound hTRPC5 shown in side view (<bold>C</bold>) and top view (<bold>D</bold>). Subunits A, B, C, and D are colored in purple, light blue, orange, and gray, respectively. Lipids are colored in gold. The approximate boundary of the cell membrane is indicated by gray lines. TMD, transmembrane domain; ICD, intracellular cytosolic domain. (<bold>E</bold>) Ribbon diagram of a single subunit with secondary structure elements represented in different colors. ARD, ankyrin repeats domain; LHD, linker-helix domain; CH1, C-terminal helix 1; CH2, C-terminal helix 2.</p><p> <supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Inhibition of WT hTRPC5 by clemizole or by HC-070.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63429-fig1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Biochemical and functional characterization of human TRPC5 (hTRPC5) constructs.</title><p>(<bold>A–C</bold>) Representative intracellular calcium signal of AD293 cells transfected with hTRPC5<sub>(1-764)</sub> evoked by 256 nM EA (<bold>A</bold>) or 14 mM extracellular calcium (<bold>B, C</bold>), and inhibited by different concentrations of HC-070 (<bold>B</bold>) or clemizole (CMZ) (<bold>C</bold>), measured by FLIPR calcium assay. Arrow 1 denotes the time point for application of buffer alone or buffer with inhibitors; arrow 2 denotes the time point for application of the activators. (<bold>D</bold>) Fluorescence size exclusion chromatography profile of full-length hTRPC5 and hTRPC5<sub>(1-764)</sub>. (<bold>E</bold>) Representative size exclusion chromatography of hTRPC5<sub>(1-764)</sub> purified in glycol-diosgenin (GDN) micelles. (<bold>F</bold>) SDS-PAGE gel of hTRPC5<sub>(1-764)</sub> eluted from size exclusion chromatography. The position of TRPC5 is labeled. Fractions that were pooled for cryo-EM analysis are denoted by asterisks.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Cryo-EM image analysis of apo human TRPC5 (hTRPC5).</title><p>(<bold>A</bold>) Representative raw micrograph recorded on K2 Summit camera. (<bold>B</bold>) Representative 2D class averages of apo hTRPC5. (<bold>C</bold>) Flowchart for cryo-EM data processing of apo hTRPC5. (<bold>D</bold>) Fourier shell correlation (FSC) curves of the two independently refined maps for unmasked (blue line, 3.9 Å) and corrected (purple line, 3 Å). Resolution estimation was based on the criterion of FSC 0.143 cut-off. (<bold>E</bold>) Angular distribution of clemizole (CMZ)-bound hTRPC5. This is a standard output from cryoSPARC. (<bold>F</bold>) FSC curve of the refined model versus EM map.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Cryo-EM map of apo human TRPC5 (hTRPC5).</title><p>(<bold>A–C</bold>) Cryo-EM map of apo hTRPC5 colored by local resolution, shown in top view (<bold>A</bold>), side view (<bold>B</bold>), and cross-section (<bold>C</bold>). The position of cross-section is shown as a dashed line in (<bold>A</bold>). (<bold>D</bold>) Cryo-EM density map (contoured at 4.1 σ, gray mesh) with atomic models superimposed.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Cryo-EM image analysis of clemizole (CMZ)-bound human TRPC5 (hTRPC5).</title><p>(<bold>A</bold>) Representative raw micrograph recorded on K2 Summit camera. (<bold>B</bold>) Representative 2D class averages of CMZ-bound hTRPC5. (<bold>C</bold>) Flowchart for cryo-EM data processing of CMZ-bound hTRPC5. (<bold>D</bold>) Fourier shell correlation (FSC) curves of the two independently refined maps for unmasked (blue line, 3.5 Å) and corrected (purple line, 2.7 Å). Resolution estimation was based on the criterion of FSC 0.143 cut-off. (<bold>E</bold>) Angular distribution of CMZ-bound hTRPC5. This is a standard output from cryoSPARC. (<bold>F</bold>) FSC curve of the refined model versus EM map.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig1-figsupp4-v2.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Cryo-EM map of clemizole (CMZ)-bound human TRPC5 (hTRPC5).</title><p>(<bold>A–C</bold>) Cryo-EM map of CMZ-bound hTRPC5 colored by local resolution, shown in top view (<bold>A</bold>), side view (<bold>B</bold>), and cross-section (<bold>C</bold>). The position of cross-section is shown as a dashed line in (<bold>A</bold>). (<bold>D</bold>) Cryo-EM density map (contoured at 3.8 σ, gray mesh) with atomic models superimposed. (<bold>E</bold>) Cryo-EM density of CMZ shown in different views (contoured at 3.7 σ). (<bold>F</bold>) Cryo-EM densities of CMZ-binding pocket in CMZ-bound hTRPC5 map (contoured at 4.6 σ). (<bold>G, H</bold>) Cryo-EM densities in HC-070-bound hTRPC5 and apo hTRPC5 maps corresponding to the CMZ-binding pocket contoured at the same σ as in (<bold>F</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig1-figsupp5-v2.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 6.</label><caption><title>Cryo-EM image analysis of HC-070-bound human TRPC5 (hTRPC5).</title><p>(<bold>A</bold>) Representative raw micrograph recorded on K2 Summit camera. (<bold>B</bold>) Representative 2D class averages of HC-070-bound hTRPC5. (<bold>C</bold>) Flowchart for cryo-EM data processing of HC-070-bound hTRPC5. (<bold>D</bold>) Fourier shell correlation (FSC) curves of the two independently refined maps for unmasked (blue line, 3.4 Å) and corrected (purple line, 2.7 Å). Resolution estimation was based on the criterion of FSC 0.143 cut-off. (<bold>E</bold>) Angular distribution of HC-070-bound hTRPC5. This is a standard output from cryoSPARC. (<bold>F</bold>) FSC curve of the refined model versus EM map.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig1-figsupp6-v2.tif"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 7.</label><caption><title>Cryo-EM map of HC-070-bound human TRPC5 (hTRPC5).</title><p>(<bold>A–C</bold>) Cryo-EM map of HC-070-bound hTRPC5 colored by local resolution, shown in top view (<bold>A</bold>), side view (<bold>B</bold>), and cross-section (<bold>C</bold>). The position of cross-section is shown as dashed line in (<bold>A</bold>). (<bold>D</bold>) Cryo-EM density map (contoured at 3 σ, gray mesh) with atomic model superimposed. (<bold>E–F</bold>) Cryo-EM density map of HC-070 shown in different views contoured at 3 and 7 σ, respectively. (<bold>G–J</bold>) Cryo-EM densities of HC-070-binding pocket in (<bold>G</bold>) HC-070-bound, (<bold>H</bold>) clemizole (CMZ)-bound, (<bold>I</bold>) apo, and (<bold>J</bold>) Pico145-bound hTRPC5 maps, contoured at 3.8 σ.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig1-figsupp7-v2.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Cryo-EM data collection, refinement, and validation statistics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top">PDB ID <break/>EMDB ID</th><th rowspan="3" valign="top">CMZ-bound hTRPC5 <break/>7D4P <break/>EMD-30575</th><th rowspan="3" valign="top">HC-070-bound hTRPC5 <break/>7D4Q <break/>EMD-30576</th><th valign="top">apo_hTRPC5</th></tr><tr><th valign="top">7E4T</th></tr><tr><th valign="top">EMD-30987</th></tr></thead><tbody><tr><td valign="top"><italic>Data collection and processing</italic></td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top"> Magnification</td><td valign="top">130,000×</td><td valign="top">165,000×</td><td valign="top">130,000×</td></tr><tr><td valign="top"> Voltage (kV)</td><td valign="top">300</td><td valign="top">300</td><td valign="top">300</td></tr><tr><td valign="top"> Electron exposure (e<sup>-</sup>/Å<sup>2</sup>)</td><td valign="top">50</td><td valign="top">50</td><td valign="top">50</td></tr><tr><td valign="top"> Defocus range (μm)</td><td valign="top">−1.5 to −2.0</td><td valign="top">−1.5 to −2.0</td><td valign="top">−1.5 to −2.0</td></tr><tr><td valign="top"> Pixel size (Å)</td><td valign="top">1.045</td><td valign="top">0.821</td><td valign="top">1.045</td></tr><tr><td valign="top"> Symmetry imposed</td><td valign="top"><italic>C4</italic></td><td valign="top"><italic>C4</italic></td><td valign="top"><italic>C4</italic></td></tr><tr><td valign="top"> Initial particle images (no.)</td><td valign="top">354,312</td><td valign="top">274,189</td><td valign="top">64,918</td></tr><tr><td valign="top"> Final particle images (no.)</td><td valign="top">90,357</td><td valign="top">114,211</td><td valign="top">29,156</td></tr><tr><td valign="top">Map resolution (Å) <break/>Fourier shell correlation threshold</td><td valign="top">2.7 <break/>0.143</td><td valign="top">2.7 <break/>0.143</td><td valign="top">3.0 <break/>0.143</td></tr><tr><td valign="top">Map resolution range (Å)</td><td valign="top">250–2.7</td><td valign="top">250–2.7</td><td valign="top">250–3.0</td></tr><tr><td valign="top"><italic>Refinement</italic></td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top"> Initial model used (PDB code)</td><td valign="top">5Z96</td><td valign="top">5Z96</td><td valign="top">5Z96</td></tr><tr><td valign="top">Model resolution (Å) <break/>Fourier shell correlation threshold</td><td valign="top">2.7 <break/>0.143</td><td valign="top">2.7 <break/>0.143</td><td valign="top">3.0 <break/>0.143</td></tr><tr><td valign="top">Model resolution range (Å)</td><td valign="top">250–2.7</td><td valign="top">250–2.7</td><td valign="top">250–3.0</td></tr><tr><td valign="top">Map sharpening B factor (Å<sup>2</sup>)</td><td valign="top">−119.0</td><td valign="top">−118.1</td><td valign="top">−119.0</td></tr><tr><td valign="top">Model composition</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Nonhydrogen atoms <break/>Protein residues <break/>Ligands</td><td valign="top"> <break/>22,472 <break/>2680 <break/>28</td><td valign="top">22,388 <break/>2672 <break/>24</td><td valign="top">22,276 <break/>2656 <break/>24</td></tr><tr><td valign="top">B factors (Å<sup>2</sup>)</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Protein <break/>ligand</td><td valign="top">95.86 <break/>91.34</td><td valign="top">120.29 <break/>124.44</td><td valign="top">140.20 <break/>133.98</td></tr><tr><td valign="top">Root-mean-square deviations</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top"> <break/>Bond lengths (Å) <break/>Bond angles (°)</td><td valign="top">0.004 <break/>0.914</td><td valign="top">0.004 <break/>0.918</td><td valign="top">0.004 <break/>0.906</td></tr><tr><td valign="top">Validation</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Validation <break/>MolProbity score <break/>Clashscore <break/>Poor rotamers (%)</td><td valign="top">1.21 <break/>4.33 <break/>0.67</td><td valign="top">1.32 <break/>5.80 <break/>0.67</td><td valign="top">1.30 <break/>5.52 <break/>1.01</td></tr><tr><td valign="top">Ramachandran plot</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Favored (%) <break/>Allowed (%) <break/>Disallowed (%)</td><td valign="top">98.78 <break/>1.22 <break/>0.00</td><td valign="top">98.63 <break/>1.37 <break/>0.00</td><td valign="top">98.93 <break/>1.07 <break/>0.00</td></tr></tbody></table></table-wrap><p>The overall architecture of inhibitor-bound hTRPC5 is similar to apo state, occupying 100 Å ×100 Å × 130 Å in three-dimensional (3D) space (<xref ref-type="fig" rid="fig1">Figure 1C–D</xref>). The fourfold symmetric channel has two-layer architecture, composed of the intracellular cytosolic domain (ICD) layer and the transmembrane domain (TMD) layer (<xref ref-type="fig" rid="fig1">Figure 1C–D</xref>). In ICD layer, the N-terminal ankyrin repeats domain (ARD) is below the linker-helix domain (LHD) region (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). The TRP helix mediates interactions with TMD. The C-terminal helix 1 (CH1) and the C-terminal helix 2 (CH2) fold back to interact with LHD and ARD (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). In TMD layer, the pre-S1 elbow, the voltage sensor-like domain (VSLD, S1-S4), and the pore domain (S5-S6) assemble in a domain-swapped fashion. Densities of several putative lipid molecules were readily observed in the TMD layer, most of which are in the grooves between VSLD and the pore domains (<xref ref-type="fig" rid="fig1">Figure 1C–D</xref>).</p></sec><sec id="s2-2"><title>The CMZ-binding site</title><p>By comparing the cryo-EM maps of hTRPC5 in complex with CMZ with both the apo state and HC-070-bound state, we found a nonprotein density within a pocket surrounded by S1-S4 and TRP re-entrant loop of VSLD in the CMZ-bound state (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>, <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5E–H</xref>). Moreover, the size and shape of this density match CMZ, suggesting this density represents CMZ. Several residues in hTRPC5 are close to CMZ molecule (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), including Y374 on S1, F414, G417 and E418 on S2, D439, M442, N443 and Y446 on S3, R492, S495 and L496 on S4, and P659 on TRP re-entrant loop (<xref ref-type="fig" rid="fig2">Figure 2C–D</xref>). Among them, F414 forms a π-π stacking interaction with the chlorophenyl ring of CMZ. Side chains of Y374, M442, Y446, and P659 show hydrophobic interactions with CMZ. Residues surrounding the CMZ-binding site are highly conserved between TRPC4 and TRPC5, in agreement with their similar selectivity for CMZ type inhibitors (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). To understand the function of CMZ interacting residues and the TRPC subtype selectivity of CMZ, we mutated CMZ interacting residues into alanines or the counterparts of TRPC3/6/7. Although all of the mutants showed surface expression (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F–G</xref>), some of them had much lower response to 14 mM extracellular calcium compared to WT channel (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). We only analyze mutants which showed more than half of WT’s response to 14 mM extracellular Ca<sup>2+</sup>. We found mutations of F414M and S495A did not change the potency of CMZ much (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="table" rid="table2">Table 2</xref>), while N443L decrease the potency (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="table" rid="table2">Table 2</xref>), suggesting N443 is one of the structural determinants of TRPC subtype selectivity for CMZ inhibition. Although N443 is not involved in polar interactions with CMZ, but it is in close proximity to CMZ and probably has Van der Waals interactions with CMZ. Replacement of N443 with Leu might alter these interactions. These results collectively confirmed this is the CMZ-binding site which carries the inhibitory function against hTRPC5.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Clemizole (CMZ) binding site in human TRPC5 (hTRPC5).</title><p>(<bold>A</bold>) Densities of CMZ and nearby residues. The map is contoured at 5.0 σ (gray mesh). CMZ and hTRPC5 are shown as sticks, colored in sky blue and purple, respectively. (<bold>B</bold>) Overview of the CMZ-binding site in hTRPC5. The dashed region denotes the binding pocket of CMZ. (<bold>C</bold>) Close-up view of the CMZ-binding site. CMZ is shown as transparent surface superimposed with sticks. Side chains of residues that interact with CMZ are shown as sticks. A cation near CMZ is shown as a magenta sphere. (<bold>D</bold>) Cartoon representation of the interactions between CMZ and hTRPC5. S1-S4 of subunit A are represented as purple ovals. Residues that interact with CMZ are labeled inside the ovals. (<bold>E</bold>) Inhibitory effect of CMZ on various hTRPC5 mutants, measured by FLIPR calcium assay (data are shown as means ± standard error, n = 3 independent experiments).</p><p> <supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Inhibitory effect of CMZ on various hTRPC5 mutants.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63429-fig2-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Sequence alignments of the transient receptor potential canonical (TRPC) channels.</title><p>Conserved residues are colored in gray. Secondary structures are indicated as cylinders (α helices) and lines (loops). Unmodeled residues are indicated as dashed line. Residues of clemizole (CMZ)-binding site, HC-070-binding site, voltage sensor-like domain (VSLD’s) cation-binding site, and zinc-binding site in CTD are indicated with blue boxes, black boxes, red boxes, and purple boxes, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Functional characterization of human TRPC5 (hTRPC5) mutants.</title><p>(<bold>A</bold>) The activation of hTRPC5 mutants by 14 mM Ca<sup>2+</sup> were normalized to wild-type channel (data are shown as means ± standard error, n = 3 independent experiments). (<bold>B–E</bold>) The dose-response curve of hTRPC5 mutants by extracellular Ca<sup>2+</sup> were normalized to wild-type channel (data are shown as means ± standard error, n = 3 independent experiments). (<bold>F–G</bold>) Surface expression levels of wild-type and hTRPC5 mutants by western blot. The biotinylated protein was detected by anti-TRPC5 antibody in (<bold>F</bold>) and anti-N-cadherin antibody in (<bold>G</bold>).</p><p> <supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Activation of hTRPC5 mutants by 14 mM Ca<sup>2+</sup> normalized to wild type hTRPC5.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63429-fig2-figsupp2-data1-v2.xlsx"/></supplementary-material> </p><p> <supplementary-material id="fig2s2sdata2"><label>Figure 2—figure supplement 2—source data 2.</label><caption><title>Activation of hTRPC5 mutants by extracellular Ca<sup>2+</sup> normalized to wild type hTRPC5.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63429-fig2-figsupp2-data2-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig2-figsupp2-v2.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>The potency of clemizole (CMZ) on various human TRPC5 (hTRPC5) constructs.</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top">TRPC5 constructs</th><th colspan="3" valign="top">CMZ</th></tr><tr><th valign="top">LogIC<sub>50</sub><sup>*</sup></th><th valign="top">Hill slope</th><th>IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr><td valign="top">hTRPC5 WT</td><td valign="top">0.49 ± 0.08</td><td valign="top">−2.52</td><td valign="top">3.07</td></tr><tr><td valign="top">Mutations in CMZ-binding pocket</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">F414M</td><td valign="top">0.33 ± 0.06</td><td valign="top">−1.45</td><td valign="top">2.15</td></tr><tr><td valign="top">N443L</td><td valign="top">1.02 ± 0.15</td><td valign="top">−2.42</td><td valign="top">10.43</td></tr><tr><td valign="top">S495A</td><td valign="top">0.48 ± 0.15</td><td valign="top">−1.21</td><td valign="top">3.03</td></tr></tbody></table><table-wrap-foot><fn><p><sup>*</sup> Data were expressed as logIC<sub>50</sub> ± SEM, n = 3.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-3"><title>The HC-070-binding site</title><p>A nonprotein density surrounded by the S5, pore helix from one subunit, and S6 of the adjacent subunit was observed in the presence of HC-070, compared with the apo state and CMZ-bound state (<xref ref-type="fig" rid="fig3">Figure 3A–B</xref>, and <xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7G–I</xref>). Furthermore, the size and shape of this density perfectly match those of HC-070, indicating this density represents HC-070 compound. HC-070 is a clover-shaped molecule with a hydroxypropyl tail, a chlorophenyl ring, and a chlorophenoxy ring, all of which extend out from the central methylxanthine core. hTRPC5 makes extensive interactions with HC-070 (<xref ref-type="fig" rid="fig3">Figure 3C–D</xref>). The side chain of F576 on pore helix forms π-π stacking interaction with the methylxanthine core of HC-070. R557 on the loop linking S5 and pore helix (linker), Q573 and W577 on pore helix form polar contacts with the hydroxypropyl tail of HC-070. F599, A602, and T603 on S6 from the adjacent subunit also stabilize the hydroxypropyl tail. F569 and L572 interact hydrophobically with the chlorophenyl ring of HC-070 (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>). The chlorophenoxy branch is close to C525, which might account for its weaker density and higher flexibility compared to other part of HC-070 (<xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7F</xref>). Residues involved in HC-070 binding are absolutely conserved between hTRPC4 and hTRPC5 but not in TRPC3/6/7 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), in agreement with the fact that HC-070 selectively inhibits TRPC4/5 with high potency compared with TRPC3/6/7 (<xref ref-type="bibr" rid="bib22">Just et al., 2018</xref>). To understand the contribution of hTRPC5 residues on the inhibitory effect of HC-070, we mutated HC-070 interacting residues into alanines and only analyze mutants with more than 50% of WT’s response to 14 mM extracellular Ca<sup>2+</sup> (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). We found that C525A does not change the potency of HC-070 much (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="table" rid="table3">Table 3</xref>), while R557A, F569A, L572A, Q573A, F599A, and T603A show decreased potency (<xref ref-type="fig" rid="fig3">Figure 3E–F</xref>, <xref ref-type="table" rid="table3">Table 3</xref>). Notably, Q573A dramatically decreased HC-070 potency (<xref ref-type="fig" rid="fig3">Figure 3F</xref>, <xref ref-type="table" rid="table3">Table 3</xref>), emphasizing the essential role of the hydrogen bond between Q573 and hydroxypropyl group of HC-070. We also mutated F599 of hTRPC5 into the Asn (N in TRPC3/6) and found that F599N increased the IC<sub>50</sub> more dramatically than F599A did, probably because F599N mutation perturbs the local hydrophobic environment of the HC-070-binding site and indirectly affects ligand binding (<xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>HC-070 binding site in human TRPC5 (hTRPC5).</title><p>(<bold>A</bold>) Densities within the HC-070-binding site. The map is contoured at 3 σ (gray mesh). HC-070 and hTRPC5 are shown in sticks, with HC-070 colored in gray. Subunits A and B are colored in purple and light blue, respectively. (<bold>B</bold>) Overview of the HC-070-binding site in hTRPC5. The dashed region marks the binding pocket of HC-070. (<bold>C</bold>) Close-up view of the HC-070-binding site. HC-070 is shown as transparent surface superimposed with stick model. Side chains of residues that interact with HC-070 are shown as sticks. (<bold>D</bold>) Cartoon representation of the interactions between HC-070 and hTRPC5. S5 of subunit A and S6 of subunit B are represented as purple and light blue ovals, respectively. Residues that interact with HC-070 are labeled inside the ovals. (<bold>E, F</bold>) Inhibitory effect of HC-070 on various hTRPC5 mutants, measured by FLIPR calcium assay (data are shown as means ± standard error, n = 3 independent experiments).</p><p> <supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Inhibitory effect of HC-070 on various hTRPC5 mutants.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63429-fig3-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig3-v2.tif"/></fig><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>The potency of HC-070 on various human TRPC5 (hTRPC5) constructs.</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top">TRPC5 constructs</th><th colspan="3" valign="top">HC-070</th></tr><tr><th valign="top">LogIC<sub>50</sub><sup>*</sup></th><th valign="top">Hill slope</th><th valign="top">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr><td valign="top">hTRPC5 WT</td><td valign="top">2.31 ± 0.10</td><td valign="top">−1.52</td><td valign="top">204.3</td></tr><tr><td valign="top">Mutations in HC-070-binding pocket</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">C525A</td><td valign="top">2.16 ± 0.15</td><td valign="top">−1.03</td><td valign="top">145.8</td></tr><tr><td valign="top">R557A</td><td valign="top">2.52 ± 0.07</td><td valign="top">−1.45</td><td valign="top">329.7</td></tr><tr><td valign="top">F569A</td><td valign="top">2.86 ± 0.15</td><td valign="top">−1.21</td><td colspan="2" valign="top">727.4</td></tr><tr><td valign="top">L572A</td><td valign="top">2.74 ± 0.17</td><td valign="top">−1.58</td><td valign="top">552.7</td></tr><tr><td valign="top">Q573A</td><td valign="top">3.10 ± 0.61</td><td valign="top">−1.75</td><td valign="top">&gt;1000</td></tr><tr><td valign="top">F599A</td><td valign="top">2.67 ± 0.29</td><td valign="top">−1.09</td><td valign="top">467.9</td></tr><tr><td valign="top">F599N</td><td valign="top">3.57 ± 1.55</td><td valign="top">−0.86</td><td valign="top">&gt;1000</td></tr><tr><td valign="top">T603A</td><td valign="top">2.68 ± 0.16</td><td valign="top">−1.20</td><td valign="top">472.7</td></tr><tr><td valign="top">T607A</td><td valign="top">2.43 ± 0.12</td><td valign="top">−3.13</td><td valign="top">268.4</td></tr></tbody></table><table-wrap-foot><fn><p><sup>*</sup> Data were expressed as logIC<sub>50</sub> ± SEM, n = 3.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-4"><title>Ion conduction pore and cation-binding sites</title><p>In TMD, pore helices, pore loops, and S6 of four protomers form the transmembrane pathway for ion permeation. Calculated pore profiles showed that the constriction is formed by the side chains of I621, N625, and Q629, which represents the lower gate of hTRPC5 (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). The smallest radius at this gate is below 1 Å, indicating the channel is in a nonconductive closed state (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). This is in agreement with the inhibitory function of CMZ and HC-070. A putative cation density inside VSLD, surrounded by E418 and E421 on S2 and N436, D439 on S3, was observed in both CMZ and HC-070 maps (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Strikingly, this putative cation is in close proximity to CMZ in CMZ-bound hTRPC5 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Similar cation density was previously observed in mTRPC4 and mTRPC5 and identified as activating calcium in TRPM2, TRPM4, and TRPM8 (<xref ref-type="bibr" rid="bib4">Autzen et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Duan et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Duan et al., 2018</xref>; <xref ref-type="bibr" rid="bib20">Huang et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Yin et al., 2019</xref>). We generate the E418Q-E421Q-D439N triple mutant (<xref ref-type="bibr" rid="bib16">Duan et al., 2019</xref>) to abolish the cation-binding capability of this site and found the channel cannot be activated by extracellular calcium anymore (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), suggesting the essential role of this site for calcium activation. Since icilin activates TRPM8 in a Ca<sup>2+</sup>-dependent manner and binds to a topologically equivalent site as CMZ (<xref ref-type="bibr" rid="bib56">Yin et al., 2019</xref>), we carried out electrophysiology experiment and used 1 mM EGTA and 1 mM EDTA to chelate intracellular Ca<sup>2+</sup> to explore whether Ca<sup>2+</sup> is required for CMZ inhibition of TRPC5. We found that CMZ could inhibit EA-elicited currents in this condition (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>), suggesting CMZ exerts its function independent of high intracellular Ca<sup>2+</sup>.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Ion conduction pore and other nonprotein densities in human TRPC5 (hTRPC5) maps.</title><p>(<bold>A</bold>) Side view of the pore region of nonconductive hTRPC5 (clemizole [CMZ]-bound). Subunits A and C are shown as ribbon and colored the same as in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Subunits B and D are omitted for clarity. Ion conduction pathway along the pore is shown as dots with key residues labeled, calculated by HOLE. Purple, green, and red dots define pore radii of &gt;2.8, 1.4–2.8, and &lt;1.4 Å, respectively. (<bold>B</bold>) Calculated pore radii of CMZ-bound hTRPC5, HC070-bound hTRPC5, and apo hTRPC5 are shown vertically. (<bold>C</bold>) Close-up view of the putative cation-binding site in transmembrane domain (TMD). Densities of the cation and the related residues are contoured at 4.6 σ and shown as gray mesh. The side chains of the residues that interact with the cation are shown as sticks. (<bold>D</bold>) Close-up view of the putative zinc-binding site in hTRPC5. Densities of the zinc ion and interacting residues are contoured at 4.3 σ and shown as gray mesh. (<bold>E</bold>) Other modeled nonprotein densities in TMD in CMZ-bound hTRPC5 are shown as sticks and colored the same as in <xref ref-type="fig" rid="fig1">Figure 1</xref>. (<bold>F</bold>) Close-up view of the putative diacylglycerol (DAG)-binding sites in hTRPC5. Densities of the DAG and interacting residues are contoured at 5 σ and shown as gray mesh. Residues that interact with DAG were labeled.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Functional characterization of various human TRPC5 (hTRPC5) mutants related to ion-binding sites.</title><p>(<bold>A–B</bold>) Representative intracellular calcium signal of AD293 cells transfected with wild-type or hTRPC5 mutant evoked by 256 nM EA (<bold>A</bold>) or 14 mM extracellular calcium (<bold>B</bold>), measured by FLIPR calcium assay. (<bold>C</bold>) Macroscopic currents of hTRPC5 recorded in whole-cell mode in calcium-free condition.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Lipid densities in human TRPC5 (hTRPC5) map.</title><p>(<bold>A</bold>) Comparison of experimental density map of diacylglycerol (DAG) (gray) (contoured at 3.2 σ) and simulated density map of lysophospholipid (yellow). Please note, the density for electron-dense phosphate head group is absent in the cryo-EM maps obtained experimentally. (<bold>B–D</bold>) Close-up views of lipid 1 (<bold>B</bold>), lipid 2 (<bold>C</bold>), and cholesteryl hemisuccinate (CHS) (<bold>D</bold>) binding sites. Subunits A and B are colored in purple and light blue, respectively. Residues that interact with lipids are shown as sticks. Insets show cryo-EM densities of these lipids, contoured at 2.3, 3.1, and 3.1 σ, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>The identification of diacylglycerol (DAG) molecule in protein sample.</title><p>(<bold>A</bold>) The HPLC chromatography of DAG (18:1-18:1) under the MRM transition 638.6 -&gt; 339.3 from buffer (left), and human TRPC5 (hTRPC5) sample (right). (<bold>B</bold>) MS/MS spectrum of lipid extractants from hTRPC5 sample. (<bold>C</bold>) Potential MS/MS fragmentation pattern of DAG, using 1,2-DAG as an example.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig4-figsupp3-v2.tif"/></fig></fig-group><p>In ICD, there is another extra density found in the ankyrin repeat 4 (AR4)-linker helix (LH1) region (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). The ion is coordinated by the side chains of H178 and C182 on the AR4-LH1 loop and C184 and C187 on the LH1 helix (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Based on the chemical environments for ion coordination, this is likely to be an HC3-type zinc-binding site, as observed previously in a bacteria glucokinase (<xref ref-type="bibr" rid="bib29">Miyazono et al., 2012</xref>). Because the zinc ions were from an endogenous source and co-purified with hTRPC5, we speculate that this is a high affinity zinc- binding site that constitutively chelates zinc. The residues coordinating the putative zinc ion are highly conserved in TRPC ion channels (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), and mutation of C176A-C178A-C181A does not affect calcium activation or EA activation (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–B</xref>), suggesting that this zinc-binding site might play other regulatory or structural roles, instead of ion channel gating.</p></sec><sec id="s2-5"><title>The lipid-binding sites</title><p>In the 2.7 Å cryo-EM maps of hTRPC5 in complex with CMZ, we observed several putative lipid molecules in the TMD (<xref ref-type="fig" rid="fig1">Figure 1C–D</xref>, <xref ref-type="fig" rid="fig4">Figure 4E</xref>). One lipid is located near the S5 and pore helix from one subunit and S6 from the adjacent subunit in the CMZ-bound hTRPC5. Its density highly resembles diacylglycerol (DAG) molecule which shows two acryl tails, but without phosphate group or headgroup of typical phospholipids (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). In agreement with our structural observation, further HPLC-MS experiments revealed that the purified protein sample contained markedly higher level of DAG in comparison with the purification buffer control (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Therefore, we tentatively assign this density as the DAG. The free hydroxyl group of this DAG molecule forms polar contacts with Q573 (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Its two hydrophobic tails interact with several hydrophobic residues: L528, Y524 on S5; F576, W577, and V579 on the pore helix; L617 on S6; and V610, I611, and L616 on S6 from adjacent subunit. We speculate that the DAG molecules observed here were carried over from host cells throughout purification procedure, because similar densities were also reported previously in the cryo-EM map of mTRPC4 and mTRPC5 (<xref ref-type="bibr" rid="bib16">Duan et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Duan et al., 2018</xref>). Unexpectedly, in the map of HC-070-bound hTRPC5, we found that the binding site of glycerol group of DAG was occupied by HC-070, while the binding site of two DAG tails was still filled by lipid-like densities (<xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7G</xref>), indicating the binding of the glycerol group of DAG and HC-070 are mutually exclusive. We observed additional lipids densities in both CMZ-bound hTRPC5 and HC-070-bound hTRPC5 maps. Lipid 1 localizes in the inner leaflet and is bound by S3, S4, and S5 from one subunit and S5, S6 from adjacent subunit (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). Lipid 2 is in the outer leaflet of the membrane and bound by S3 and S4 (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). There is one putative cholesteryl hemisuccinate (CHS) molecule which is sandwiched by S1, S4 from one subunit and S5 from adjacent subunit (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>). Densities similar to the putative CHS were observed previously in corresponding positions in TRPM4 and TRPCs (<xref ref-type="bibr" rid="bib4">Autzen et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Duan et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Duan et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Tang et al., 2018</xref>). It is previously reported that this putative CHS-binding site is important for the activation of mTRPC5 (<xref ref-type="bibr" rid="bib16">Duan et al., 2019</xref>).</p></sec><sec id="s2-6"><title>Structure comparison of hTRPC5 structures at different states</title><p>The overall structures of hTRPC5 at different states are highly similar, with RMSD of 1.456 Å between CMZ-bound hTRPC5 and apo state; 0.926 Å between HC-070-bound hTRPC5 and apo state, although there is a little structural variation in details (<xref ref-type="fig" rid="fig5">Figure 5</xref>). In the TMD, the bottom of S3 segment and the S2-S3 linker in HC-070-bound structure have small conformational change compared to the apo hTRPC5 (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), which may be due to the HC-070 binding.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Structure comparison between clemizole (CMZ)-bound human TRPC5 (hTRPC5), HC-070-bound hTRPC5, and apo hTRPC5 in transmembrane domain (TMD).</title><p>(<bold>A</bold>) The overall conformational difference in TMD between these three structures. All the structures are shown as cartoon, with apo hTRPC5 colored in gray, CMZ-bound hTRPC5 in purple, and HC-070-bound hTRPC5 in light blue. (<bold>B</bold>) Close-up view of the structure variations of bottom of S3 segment and the S2-S3 linker between HC-070-bound and apo hTRPC5 structures.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig5-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>TRPC channels, especially TRPC5 and TRPC6, are putative drug targets. Recently, two distinct inhibitor-binding sites were identified in the hTRPC6 channel (<xref ref-type="bibr" rid="bib5">Bai et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Tang et al., 2018</xref>). During the editorial process of this work, inhibitor binding sites were also identified in TRPC4 (<xref ref-type="bibr" rid="bib50">Vinayagam et al., 2020</xref>) and TRPC5 (<xref ref-type="bibr" rid="bib52">Wright et al., 2020</xref>). Together with the sites identified in this study, we classify them into three groups, namely inhibitor-binding pocket (IBP) A-C (<xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). IBP-A inside the VSLD is accessible from the intracellular side (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Inhibitors that bind IBP-A, such as CMZ and GFB-8438, need to penetrate the plasma membrane first before reaching their binding site in VSLD. CMZ, M084, and AC1903 are benzimidazole derivatives which can inhibit TRPC5 with IC<sub>50</sub> values at 1.0–1.3, 8.2, and 14.7 μM, respectively (<xref ref-type="bibr" rid="bib39">Richter et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Zhou et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Zhu et al., 2015</xref>). Their similar chemical structures suggest that they probably share a common binding site at IBP-A (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A–C</xref>). CMZ is 10- and 26-fold more potent against TRPC5 than TRPC3/6 and TRPC7, respectively (<xref ref-type="bibr" rid="bib39">Richter et al., 2014</xref>). Among the CMZ interacting residues, E418, D439, M442, R492 are identical between TRPC4/5 and TRPC3/6/7, whereas residue Y374 in TRPC5 is Phe, F414 is Met, N443 is Leu, Y446 is Phe, S495 is Tyr, and L496 is Met in TRPC3/6/7 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). We found that F414M mutation in hTRPC5 does not change the potency of CMZ, while N443L decreases its potency (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="table" rid="table2">Table 2</xref>), highlighting the importance of N443 on CMZ selectivity. GFB-8438, GFB-9289, and GFB-8749 are piperazinone/pyridazinone derivatives that inhibit TRPC4 and TRPC5 channels. Structure of zebrafish TRPC4 in complex with these inhibitors showed that they also bind inside VSLD (<xref ref-type="bibr" rid="bib50">Vinayagam et al., 2020</xref>). GFB-8438 interacts with H369, Y646, L495, Y373, S488, M441, N442, F413, and R491 of zebrafish TRPC4 which are equivalent to H370, Y650, L496, Y374, S489, M442, N443, F414, and R492 in hTRPC5 (<xref ref-type="bibr" rid="bib50">Vinayagam et al., 2020</xref>). Therefore, both CMZ and GFB-8438 share a common set of interacting residues on hTRPC5 including L496, Y374, M442, N443, and R492. More importantly, both CMZ and GFB-8438 have several nonoverlapping interacting residues on hTRPC5, suggesting that structure-based hybridization of CMZ and GFB-8438 might exploit more interacting residues on hTRPC5 and thus enhance the inhibitor potency and selectivity. Although VSLD has lost the voltage sensing function, it plays an important structural and functional role in TRP channels. Based on the gating model of TRPV1, channel activation is associated with relative movements between VSLD and pore (<xref ref-type="bibr" rid="bib8">Cao et al., 2013</xref>; <xref ref-type="bibr" rid="bib18">Gao et al., 2016</xref>) and thus, stabilization of VSLD in an inactive conformation might be a common scheme to inhibit channel opening. Indeed, AM-1473, a potent antagonist of hTRPC6, was found to bind at IBP-A in hTRPC6 as well (<xref ref-type="bibr" rid="bib5">Bai et al., 2020</xref>). Moreover, IBP-A is the AMTB and TC-I 2014-binding sites in TRPM8 (<xref ref-type="bibr" rid="bib14">Diver et al., 2019</xref>), 2-APB-binding site in TRPV6 (<xref ref-type="bibr" rid="bib43">Singh et al., 2018</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). The studies suggest that VSLD of TRP channels is a hotspot for drug discovery.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Inhibitor-binding pockets of transient receptor potential canonical (TRPCs) in transmembrane domain (TMD).</title><p>(<bold>A</bold>) Clemizole (CMZ)-binding pocket in human TRPC5 (hTRPC5) is shown in side view and bottom view. The TRPC5 structure is shown as cylinder with CMZ compound shown as spheres and colored in sky blue. Each subunit of TRPC5 is colored the same as in <xref ref-type="fig" rid="fig1">Figure 1</xref>. (<bold>B–C</bold>) HC-070-binding pocket in hTRPC5 structure and BTDM-binding pocket in TRPC6 structure are shown in side view and bottom view. HC-070 is shown as spheres and colored in gray. The densities of BTDM are shown as red mesh.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Ligand-binding sites in transient receptor potential (TRP) family.</title><p>(<bold>A</bold>) Different ligands bind in IBP-A of TRPC4, TRPC5, TRPC6, TRPM8, and TRPV6. One subunit of different transient receptor potential canonicals (TRPCs) is shown as cartoon and colored in purple. Different ligands are shown as sticks and in various colors. (<bold>B</bold>) Different ligands bind in IBP-B of TRPCs. One subunit and the adjacent subunit are colored in purple and light blue, respectively. (<bold>C</bold>) Different ligands bind in IBP-C of TRPC6 and TRPV1. The density of BTDM is shown as red mesh and other modeled ligands are shown as sticks.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Comparison of chemical structures of different TRPC5 ligands.</title><p>(<bold>A–C</bold>) Benzimidazole derivatives inhibitors: clemizole (CMZ) (<bold>A</bold>), M084 (<bold>B</bold>), and AC1903 (<bold>C</bold>). (<bold>D–F</bold>) Piperazinone/pyridazinone derivatives inhibitors: GFB-8438 (<bold>D</bold>), GFB-8749 (<bold>E</bold>), and GFB-9289 (<bold>F</bold>). (<bold>G–I</bold>) Xanthine derivatives ligands: inhibitors HC-070 (<bold>G</bold>), Pico145 (<bold>H</bold>), and activator AM237 (<bold>I</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-fig6-figsupp2-v2.tif"/></fig></fig-group><p>IBP-B located in the pore domain is sandwiched at the subunit interface (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). HC-070 binds at IBP-B which is close to the extracellular side. Strikingly, IBP-B is partially occupied by the glycerol group of DAG molecule in the map of CMZ-bound hTRPC5 or apo hTRPC5 (<xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7G–I</xref>). Previous studies showed that some mutations in this lipid-binding site in mTRPC5, such as F576A and W577A double mutations, render mTRPC5 unresponsive to EA stimulation (<xref ref-type="bibr" rid="bib16">Duan et al., 2019</xref>). This lipid-binding site also plays an important role in the gating of DAG-activated hTRPC3/6 channels. Mutation of W680 to alanine in hTRPC6, corresponding to W577A in hTRPC5, abolished OAG activation of hTRPC6 (<xref ref-type="bibr" rid="bib5">Bai et al., 2020</xref>). Mutations of glycine residues in hTRPC6/3, corresponding to G606 in hTRPC5, blunted PLC-mediated activation of TRPC6/3, altered responses to DAGs of TRPC3, and also changed the pattern of photoactivation of TRPC6/3 by a photo-switchable DAG analogue, OptoDArG (<xref ref-type="bibr" rid="bib26">Lichtenegger et al., 2018</xref>). Mutation of this glycine residue into alanine in TRPC3 removed channel desensitization upon PLC activation and increased efficacy of GSK1702934A by maintaining the long-open state (<xref ref-type="bibr" rid="bib47">Svobodova et al., 2019</xref>). E672A, F675A, W680A, N702A, Y705A, and V706A mutants of TRPC6 (corresponding to F569, L572, W577, F599, A602, and T603 in hTRPC5) maintained normal membrane surface expression but completely abolished the response to OAG (<xref ref-type="bibr" rid="bib5">Bai et al., 2020</xref>). These data concertedly suggest that the DAG- binding pocket observed here in hTRPC5 is also structurally conserved in TRPC3/6 and is essential for TRPC3/6 channel activation by DAG and its analogues, such as OAG. Pharmacological compounds binding at IBP-B might affect TRPC channel gating either by acting on TRPC directly or by perturbing the normal function of DAG. Here, we observed that the binding of HC-070 at this site replaces the glycerol group of DAG, stabilizes hTRPC5 in a closed state, and thus inhibits channel opening. The residues involved in HC-070 binding are absolutely identical between hTRPC5 and hTRPC4, but they share only 20% similarities between TRPC4/5 and TRPC3/6/7 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), which explains the high selectivity of HC-070 for TRPC4/5 over TRPC3/6/7 (<xref ref-type="bibr" rid="bib22">Just et al., 2018</xref>). In addition, HC-070 shows inhibitory effect on heterotetrameric hTRPC1: C5 and hTRPC1: C4 with relatively lower potency compared to homotetrameric hTRPC4/5 (<xref ref-type="bibr" rid="bib22">Just et al., 2018</xref>), probably because of the lower sequence identity between TRPC4/5 and TRPC1 (46% according to the sequence alignment) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Indeed, through mutagenesis, we found that many residues participating in interactions between HC-070 and hTRPC5 are sensitive to alanine mutations (<xref ref-type="fig" rid="fig3">Figure 3E–F</xref>). It is reported that Pico145, an HC-070 analogue, is more potent against hTRPC4/5 than HC-070 (<xref ref-type="bibr" rid="bib22">Just et al., 2018</xref>), possibly due to the substitution of chloride with trifluoromethoxy group on the chlorophenoxy ring of HC-070 (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2G–H</xref>). Indeed, recent structure study showed that Pico145 binds to hTRPC5 channel using a similar pose as HC-070, except the chlorophenoxy ring with a trifluoromethoxy group on it inserts into a cavity surrounded by L521, Y524, F576, and V610 of hTRPC5 (<xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7J</xref>; <xref ref-type="bibr" rid="bib52">Wright et al., 2020</xref>). Another HC-070 analogue, AM237, is a TRPC5 activator with EC<sub>50</sub> around 15–20 nM (<xref ref-type="bibr" rid="bib28">Minard et al., 2019</xref>), and AM237 activates homomeric hTRPC5 channel instead of the heterotetrameric TRPC1: C5 channel (<xref ref-type="bibr" rid="bib28">Minard et al., 2019</xref>), suggesting that AM237 also binds at IBP-B which is at the interface between adjacent subunits. Compared with Pico145, AM237 has an additional chloride atom on the phenoxy ring (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2I</xref>), which makes the phenoxy group larger and this chloride atom might be in clash with L521 of hTRPC5. Therefore, AM237 might activate hTRPC5 by pushing L521 on S5 using its chloride-phenoxy group (<xref ref-type="bibr" rid="bib52">Wright et al., 2020</xref>). Consistent with our results of HC-070-binding site mutants, mutations in IBP-B, including Q573T, F576A, and W577A, decrease the potency of AM237 on hTRPC5 (<xref ref-type="bibr" rid="bib52">Wright et al., 2020</xref>). Recently, it is reported that an hTRPC6 agonist AM-0883 binds at IBP-B as well (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>; <xref ref-type="bibr" rid="bib5">Bai et al., 2020</xref>). The identification of DAG lipid, TRPC inhibitor, and TRPC activator binding at IBP-B suggests that it is a common modulatory ligand-binding site in TRPC channels.</p><p>IBP-C is between VSLD and pore domain, formed by S3, S4, S4-S5 linker from one subunit and S5-S6 from the adjacent subunit (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). BTDM, a high affinity inhibitor of hTRPC6, binds at IBP-C (<xref ref-type="fig" rid="fig6">Figure 6C</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>; <xref ref-type="bibr" rid="bib48">Tang et al., 2018</xref>). When BTDM is not supplied, IBP-C is occupied by a putative phospholipid (<xref ref-type="bibr" rid="bib5">Bai et al., 2020</xref>). In TRPC4/5, mutations of G503/G504 to serine on S4-S5 linker lead to constitutive activation of the channels (<xref ref-type="bibr" rid="bib6">Beck et al., 2013</xref>). In addition, vanilloid agonist resiniferatoxin (RTX), vanilloid antagonist capsazepine, and an endogenous phosphatidylinositol bind at IBP-C on TRPV1 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>; <xref ref-type="bibr" rid="bib8">Cao et al., 2013</xref>; <xref ref-type="bibr" rid="bib18">Gao et al., 2016</xref>). These data together suggest that IBP-C is important for the gating of both TRPC and TRPV channels.</p><p>In summary, our structures of hTRPC5 reported here have uncovered the binding pockets for two distinct classes of inhibitors in high-resolution details. Moreover, the structures suggest that these inhibitors inhibit the hTRPC5 channel by stabilizing it in an apo-like closed state. Further structural comparisons with previously reported TRPC channel structures have revealed three common IBPs in TRPC channels. Our studies paved the way for further mechanistic investigations and structure-based drug development.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) <break/>or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Gene (<italic>Homo sapiens</italic>)</td><td>hTRPC5</td><td>This paper</td><td>NCBI Reference sequence: NM_012471</td><td>Provided by Dr. Xiaolin Zhang, Dizal Pharmaceutical Company</td></tr><tr><td>Recombinant DNA reagent</td><td>hTRPC5</td><td>This paper</td><td/><td>Subcloned into a pBM Bacmam vector with N-terminal GFP-MBP tag</td></tr><tr><td>Recombinant DNA reagent</td><td>hTRPC5</td><td>This paper</td><td/><td>Subcloned into a pCDNA3.1 vector with no tag</td></tr><tr><td>Recombinant DNA reagent</td><td>hTRPC5<sub>1-764</sub></td><td>This paper</td><td/><td>Subcloned into a pBM Bacmam vector with N-terminal GFP-MBP tag</td></tr><tr><td>Cell line (FreeStyle 293 F)</td><td>FreeStyle 293 F</td><td>Thermo Fisher Scientific</td><td>R79007</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_D603">CVCL_D603</ext-link></td></tr><tr><td>Cell line (AD-293)</td><td>AD-293</td><td>Agilent</td><td>240085</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_9804">CVCL_9804</ext-link></td></tr><tr><td>Cell line (Sf9)</td><td>Sf9</td><td>Thermo Fisher Scientific</td><td>12659017</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0549">CVCL_0549</ext-link></td></tr><tr><td>Antibody</td><td>Anti-TRPC5 (rabbit polyclonal)</td><td>Proteintech</td><td>25890–1-AP</td><td>1:1000 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2880285">AB_2880285</ext-link></td></tr><tr><td>Antibody</td><td>Anti-N-Cadherin (rabbit polyclonal)</td><td>Proteintech</td><td>22018–1-AP</td><td>1:3000 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2813891">AB_2813891</ext-link></td></tr><tr><td>Chemical compound, drug</td><td>Clemizole</td><td>CAYMAN</td><td>17695</td><td/></tr><tr><td>Chemical compound, drug</td><td>HC-070</td><td>MedChemExpress (MCE)</td><td>31244</td><td/></tr><tr><td>Chemical compound, drug</td><td>(-)-Englerin A</td><td>PanReac AppliChem</td><td>A8907</td><td/></tr><tr><td>Software, algorithm</td><td><ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/download/special-version-for-phase-plate-gctf_v1-18/">Gctf_v1.18</ext-link></td><td><xref ref-type="bibr" rid="bib58">Zhang, 2016</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/26592709">26592709</ext-link></td><td/><td/></tr><tr><td>Software, algorithm</td><td><ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/download/gautomatch-056/">Gautomatch v0.56</ext-link></td><td>K. Zhang, MRC LMB (<ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/research/locally-developed-software/zhang-software/">https://www2.mrc-lmb.cam.ac.uk/research/locally-developed-software/zhang-software/</ext-link>)</td><td/><td/></tr><tr><td>Software, algorithm</td><td>RELION-3.0</td><td><xref ref-type="bibr" rid="bib62">Zivanov et al., 2018</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/30412051">30412051</ext-link></td><td/><td/></tr><tr><td>Software, algorithm</td><td>PHENIX 1.18.1–3865</td><td><xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/20124702">20124702</ext-link></td><td/><td/></tr><tr><td>Software, algorithm</td><td>HOLE2 v2.2.005</td><td><xref ref-type="bibr" rid="bib44">Smart et al., 1996</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/9195488">9195488</ext-link></td><td/><td/></tr><tr><td>Software, algorithm</td><td>cryoSPARC v3.1</td><td><xref ref-type="bibr" rid="bib37">Punjani et al., 2017</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/28165473">28165473</ext-link></td><td/><td/></tr><tr><td>Software, algorithm</td><td>Chimera-1.13</td><td><xref ref-type="bibr" rid="bib34">Pettersen et al., 2004</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/15264254">15264254</ext-link></td><td/><td/></tr><tr><td>Other</td><td>Rhod-2/AM</td><td>AAT Bioquest</td><td>21062</td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture</title><p>Sf9 cells (from Thermo Fisher Scientific) were cultured in Sf-900 III SFM medium (Gibco) at 27°C. HEK 293 F cells (from Thermo Fisher Scientific) grown in Free Style 293 medium + 1% FBS at 37°C were transfected for electrophysiology and FSEC. HEK 293 F cells grown in SMM-293TI medium + 1% FBS at 37°C were used for baculovirus infection and protein purification. AD293 cells (from Agilent) were cultured in basic DMEM (Gibco) + 10% FBS medium at 37°C for FLIPR calcium assay and surface expression level detection. All these cell lines were free of mycoplasma contamination detected by MycoBlue Mycoplasma Detector assay (Vazyme, D101-02), but their identities were not further authenticated.</p></sec><sec id="s4-2"><title>FSEC</title><p>The cDNA of hTRPC5 and related mutants were cloned into a homemade BacMam vector with N-terminal GFP-MBP tag (<xref ref-type="bibr" rid="bib25">Li et al., 2017</xref>). The expression levels of various hTRPC5 constructs were screened by FSEC (<xref ref-type="bibr" rid="bib24">Kawate and Gouaux, 2006</xref>). Expression constructs were transfected into HEK293F cells using PEI. 40 hr post-transfection, cells were harvested by centrifuge at 5000 rpm for 5 min. Then the cells were solubilized by 1% (w/v) LMNG, 0.1% (w/v) CHS in TBS buffer (20 mM Tris-HCl, pH 8.0 at 4°C, and 150 mM NaCl) with 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin for 30 min at 4°C. Supernatants were collected after centrifuge at 40,000 rpm for 30 min and were loaded onto Superose-6 Increase (GE Healthcare) for FSEC analysis.</p></sec><sec id="s4-3"><title>Whole cell recording</title><p>To detect the inhibition of CMZ on TRPC5, we used EA to activate hTRPC5 in whole cell recordings; 800 ng of nontagged full-length hTRPC5 in pCDNA3.1 vector and 200 ng of home-made GFP-MBP vector were co-transfected into HEK293F cell. 40 hr post-transfection, the cells were plated on cover glass for recording. For the whole cell recording, the bath solution contains 140 NaCl, 5 CsCl, 10 EGTA, 1 MgCl<sub>2</sub>, 10 glucose, and 10 HEPES (pH = 7.4, adjusted by NaOH) in mM and the pipette solution was 110 CsMe, 25 CsCl, 2 MgCl<sub>2</sub>, 1 EDTA, 1 EGTA, and 30 HEPES (pH = 7.4 adjusted by CsOH) in mM to keep low calcium condition for the recording; 200 nM EA in bath solution was used for channel activation and 50 μM CMZ was used for channel inhibition. Patch electrodes were pulled by a horizontal microelectrode puller (P-1000, Sutter Instrument Co) to a tip resistance of 2.0–4.0 MΩ for recording. The TRPC5 currents were recorded in gap-free mode at holding potential of −60 mV through an Axopatch 200B amplifier (Axon Instruments). Data was further analyzed by pCLAMP 10.4 software. We observed similar results for three cells and one representative trace was shown.</p></sec><sec id="s4-4"><title>FLIPR calcium assay</title><p>AD293 cells cultured on 10 cm dish (grown in Dulbecco's modified Eagle's medium + 10% FBS + 13.9 μg/ml streptomycin + 6.7 μg/ml penicillin, 37°C) at 90-100% confluence were digested with trypsin-EDTA (0.25%) (Gibco) and suspended with 5 ml culture medium for each 10 cm dish. Then the suspended cell culture was further diluted for 5.4- to 7-fold with culture medium and seeded onto black well, clear bottom, poly-D-lysine-coated 96-well plate (Costar) and cultured overnight. We use full-length nontagged hTRPC5 construct for FLIPR assay unless indicated otherwise. hTRPC5 plasmids were transfected into AD293 cells (60-80% confluence) with PEI. 30–40 hr post-transfection, culture medium was discarded and cells were incubated with 50 μl per well of 4 μM Rhod-2/AM (AAT Bioquest) in TARODES’s buffer (10 mM HEPES, 150 mM NaCl, 4 mM KCl, 2 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 11 mM glucose, pH 7.4) supplemented with 0.02% Pluronic F-127 (Sigma) for 5 min in dark at room temperature. Then dye was removed and replaced with 50 μl of TARODE’s buffer per well. The application of compounds and detection of intracellular calcium elevation were performed using FLIPR-TETRA (Molecular Devices) at room temperature (25–27°C). Fluorescence signals were read with excitation/emission at 510–545/565–625 nm.</p><p>For dose-response activation curves of WT and mutants by extracellular Ca<sup>2+</sup>, baseline fluorescence of the plate was measured for 30 s, followed by addition of 50 μl of TARODE’s buffer containing a series of concentration of Ca<sup>2+</sup>. Final concentrations for extracellular Ca<sup>2+</sup> were 2, 6.148, 8.222, 11.333, 16, 23, 33.5, and 49.25 mM. The normalized signal was calculated as follows: For each well, the average value of fluorescence from 0 to 20 s was considered as the ‘start fluorescence’; the average of fluorescence from 309 to 328 s was considered as the ‘end fluorescence’. The value of ‘end fluorescence’ minus ‘start fluorescence’ was considered as ‘signal value’ for each well. The ‘signal value’ of each construct activated by each concentration of Ca<sup>2+</sup> was divided by that of WT activated by 49.25 mM Ca<sup>2+</sup>, resulted in ‘% WT’.</p><p>For the inhibition curves, baseline fluorescence of the plate was measured for 30 s, followed by addition of 50 μl of buffer A (TARODE’s buffer containing a series of concentration of CMZ or HC-070). Fluorescence was measured for another 210 s, followed by addition of 50 μl of buffer B (TARODE’s buffer containing additional high calcium and a series of concentration of CMZ or HC-070). Then fluorescence was measured for 300 s.</p><p>Buffer A contains 2× concentration of working concentration of inhibitor. As for CMZ, it was serially diluted to concentrations of: 205, 102.5, 51.25, 25.625, 12.8, 6.4, 3.2, 1.6, 0.8, 0.4 μM. As for HC-070, it was serially diluted to concentrations of: 4000, 2000, 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.81 nM. Buffer B is TARODE’s buffer containing additional 36 mM Ca<sup>2+</sup> and a series of working concentration of inhibitor (102.5, 51.25, 25.625, 12.8, 6.4, 3.2, 1.6, 0.8, 0.4, 0.2 μM for CMZ and 2000, 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.81, 3.9 nM for HC-070, respectively). Final concentration of calcium for activation was 14 mM. The concentration series of CMZ was 102.5, 51.25, 25.625, 12.8, 6.4, 3.2, 1.6, 0.8, 0.4, 0.2 μM. The concentration series of HC-070 was 2000, 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.81, 3.9 nM. For each construct, there were two controls: for control-Max, buffer A was replaced by TARODE’s buffer; for control-Min, both buffer A and buffer B were replaced by TARODE’s buffer.</p><p>To calculate the normalized signal values for inhibition experiments, the averaged fluorescence value from 210 to 230 s of each well was considered as the ‘start fluorescence’; the average of fluorescence value of last 20 time points was considered as the ‘end fluorescence’. The value of ‘end fluorescence’ minus ‘start fluorescence’ was considered as ‘signal value’ for each well. The ‘signal value’ of each well was subtracted by ‘signal value’ of control-Min, resulting in a value considered as ‘response value’. The ‘response value’ of each well was divided by ‘response value’ of control-Max to obtain an ‘internal normalized response’. The ‘internal normalized responses’ were further multiplied by X% (X%: ‘response value’ of each construct activated by 14 mM Ca<sup>2+</sup> divided by that of WT, as shown in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>), resulting in a value considered as ‘normalized RFU (% WT)’. IC<sub>50</sub> was obtained by fitting the data of ‘% WT’ into function: Y=Bottom + (Top-Bottom)/(1+10<sup>(LogIC50-X)*HillSlope</sup>).</p><p>Three independent experiments were performed on different days (biological replicates), with each experiment containing three replicates (technique replicates).</p></sec><sec id="s4-5"><title>Surface biotinylation and western blot</title><p>Thirty-six hours post-transfection, cells transfected with full-length nontagged TRPC5 plasmids in six-well plate were washed with PBS (pH = 8) for three times. Then 500 μl of 1.5 mM Sulfo-NHS-LC-biotin (APExBIO) in PBS (pH = 8) was added to each well and incubated at room temperature for 1 hr. Then the Sulfo-NHS-LC-biotin solution was discarded, followed by addition of ice-cold TBS +10 mM glycine (pH = 8) to terminate the reaction. Then the cells were washed with TBS and then lysed with TBS+1% MNG for 40 min on ice, followed by centrifugation at 16,125×<italic>g</italic> for 20 min. Supernatants were incubated with streptavidin-agarose beads (SIGMA) for 2 hr at 4°C, followed by centrifugation at 1000×<italic>g</italic> to remove flow-through. Beads were washed with lysis buffer for four times, followed by elution with elution buffer (50 mM Tris pH 7.5, 150 mM NaCl, 3 mM biotin, 100 mM dithiothreitol [DTT], 2% SDS) at room temperature or 85°C for 7 min. The eluates were separated on 10% gradient SDS-PAGE gel and N-cadherin was detected by western blot using antibodies against N-cadherin (1:3000) (Proteintech) as an internal control to normalize loading volumes of the samples. Then TRPC5 protein was detected using antibodies against TRPC5 (1:1000) (Proteintech).</p></sec><sec id="s4-6"><title>Protein expression and purification</title><p>The BacMam expression system was used for large-scale expression of hTRPC5<sub>1-764</sub> as previously reported (<xref ref-type="bibr" rid="bib48">Tang et al., 2018</xref>). Briefly, hTRPC5<sub>1-764</sub> was subcloned into a home-made BacMam vector with N-terminal GFP-MBP tag. The Bacmid was then generated by transforming this construct into DH10Bac <italic>Escherichia coli</italic> cells. Baculovirus was harvested about 7 days post-transfection of bacmid into Sf9 cells cultured in Sf-900 III SFM medium (Gibco) at 27 °C. P2 baculovirus was produced using Bac-to-Bac system. P2 virus was added to HEK293F cells at a ratio of 1:12.5 (v/v) when the cells were grown to a density of 2.0 × 10<sup>6</sup>/ml in SMM 293T-I medium (Sino Biological Inc) supplemented with 1% FBS under 5% CO<sub>2</sub> in a shaker at 130 rpm at 37°C. After virus infection for 12 hr, 10 mM sodium butyrate was added and temperature was lowered to 30°C. Cells were harvested 48 hr post-infection and washed twice using TBS buffer. Cell pellets were collected and stored at −80°C for further purification.</p><p>Cell pellets were resuspended in TBS buffer supplemented with 1% (w/v) LMNG, 0.1% (w/v) CHS, 1 mM DTT, 1 mM phenylmethanesulfonylfluoride, and protease inhibitors, including 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin. The mixture was incubated at 4°C for 1 hr. After ultracentrifugation at 40,000 rpm for 1 hr in Ti45 rotor (Beckman), the supernatant was loaded onto 7 ml MBP resin. The resin was rinsed with wash buffer 1 (wash buffer 2 + 1 mM ATP + 10 mM MgCl<sub>2</sub>) and wash buffer 2 (TBS + 40 μM glycol-diosgenin [GDN] + 0.005 mg/ml SPLE + 1 mM DTT) subsequently. Proteins were eluted with 80 mM maltose in wash buffer 2. The eluate was concentrated using a 100 kDa cut-off concentrator (Millipore) after digestion with H3C protease at 4°C overnight. hTRPC5 protein was further purified by size exclusion chromatography (Superose-6 Increase) in buffer containing TBS, 40 μM GDN, 0.005 mg/ml SPLE, and 1 mM tris(2-carboxyethyl) phosphine. The peak fractions corresponding to tetrameric TRPC5 channel were collected and concentrated to A<sub>280</sub> = 1.0 with estimated concentration of 0.7 mg/ml for cryo-EM sample preparation.</p></sec><sec id="s4-7"><title>Cryo-EM sample preparation and data collection</title><p>Purified protein was first mixed with 100 μM Ca<sup>2+</sup> and then mixed with 500 μM CMZ or 50 μM HC-070, respectively. The sample with EA was prepared in two batches. In the first batch, protein added with 100 μM Ca<sup>2+</sup> was incubated with 6.5 μM EA for 30 min before concentration. In the second batch, 0.12 μl of 5 mM EA in 50% DMSO was added to 6 μl concentrated protein in the presence of 5 mM Ca<sup>2+</sup>. We did not observe obvious difference in final cryo-EM reconstructions between the two EA samples. Therefore, we combined data collected from these two batches into the EA dataset. After incubation with ligands for 30 min on ice, the mixtures were ultracentrifugated at 25,000 rpm for 30 min in TLA55 rotor (Beckman) and the supernatants were used for cryo-EM sample preparation. Aliquots of 2.5 μl mixture were placed on graphene oxide grids as previously reported (<xref ref-type="bibr" rid="bib36">Phulera et al., 2018</xref>). Grids were blotted at 100% humidity and flash-frozen in liquid ethane cooled by liquid nitrogen using Vitrobot Mark I (FEI). Grids were then transferred to a Titan Krios (FEI) electron microscope that was equipped with a Gatan GIF Quantum energy filter and operated at 300 kV accelerating voltage. Image stacks were recorded on a Gatan K2 Summit direct detector in super-resolution counting mode using SerialEM at a nominal magnification of 165,000× (HC-070-bound, calibrated pixel size of 0.821 Å/pixel) or 130,000× (CMZ-bound and apo state, calibrated pixel size of 1.045 Å/pixel), with a defocus ranging from −1.5 to −2.0 μm. Each stack of 32 frames was exposed for 7.1 s, with a total dose about 50 e<sup>-</sup>/ Å <sup>2</sup> and a dose rate of 8 e<sup>-</sup> per pixel per second on detector.</p></sec><sec id="s4-8"><title>Image processing</title><p>All of the datasets were processed with similar workflow. The collected image stacks were motion-corrected by MotionCor2 (<xref ref-type="bibr" rid="bib59">Zheng et al., 2017</xref>). After motion correction, good micrographs were manually selected, then GCTF (<xref ref-type="bibr" rid="bib58">Zhang, 2016</xref>) was used for CTF estimation. Particles were auto-picked using Gautomatch (kindly provided by Kai Zhang) based on the projection of hTRPC6 map (EMDB: EMD-6856), respectively. After one-round or two-rounds of reference-free two-dimensional (2D) classification, particles in classes with good features were selected for 3D classification with previous hTRPC6 map (EMDB: EMD-6856) low-pass filtered to 18 Å as the initial model using RELION-3.0 (<xref ref-type="bibr" rid="bib62">Zivanov et al., 2018</xref>) with C1 symmetry. After 3D classification, particles in good classes with clearly visible α-helices in TMD were selected for further homogeneous refinements in cryoSPARC (<xref ref-type="bibr" rid="bib37">Punjani et al., 2017</xref>) using C4 symmetry, because we found that refinement in cryoSPARC gave better Fourier shell correlations (FSCs) and maps for TRPC5 datasets. Reported resolutions are based on the gold-standard FSC 0.143 criterion after correction of masking effect (<xref ref-type="bibr" rid="bib10">Chen et al., 2013</xref>). The map was sharpened with a B factor determined by cryoSPARC automatically.</p></sec><sec id="s4-9"><title>Model building, refinement, and validation</title><p>The previously reported TRPC4 (PDB: 5Z96) was used as the starting model and docked into the HC-070-bound or CMZ-bound hTRPC5 maps in Chimera (<xref ref-type="bibr" rid="bib34">Pettersen et al., 2004</xref>), respectively. The fitted model was manually adjusted in COOT (<xref ref-type="bibr" rid="bib17">Emsley et al., 2010</xref>), keeping the side chains of conserved residues and substituting nonconserved residues based on the sequence alignment between mTRPC5 and hTRPC5. The ligands models were generated using elbow module (<xref ref-type="bibr" rid="bib32">Moriarty et al., 2009</xref>) in PHENIX (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>). The ligands and phospholipids were manually docked into densities and refined using COOT. The models were further refined against the corresponding maps with PHENIX (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>).</p></sec><sec id="s4-10"><title>Quantification and statistical analysis</title><p>The local resolution map was calculated using cryoSPARC. The pore radius was calculated using HOLE (<xref ref-type="bibr" rid="bib44">Smart et al., 1996</xref>). The inhibition curves were calculated using GraphPad Prism 8. RMSD was calculated using PyMOL in all-atom mode.</p></sec><sec id="s4-11"><title>Identification of DAG molecule in hTRPC5 protein sample by LC-MS analysis</title><p>To prepare samples for LC–MS analysis, 20 μl of purified hTRPC5 (7 μM) in the wash buffer 1 (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 40 μM GDN, 0.005 mg/ml SPLE, and 1 mM DTT) was added into 400 μl isopropanol, vortexed and extracted by ultrasonication for 1 min. After centrifugation at 14,000 rpm for 10 min at 4°C, the supernatant was transferred into vial for further LC–MS analysis.</p><p>UPLC (Waters ACQUITY I-Class system) coupled with tandem ESI-Triple quadrupole mass spectrometry (Waters Xevo TQ-S Micro) was used to analyze 2 μl lipid extractants. An ACQUITY UPLC BEH Amide column (1.7 μm, 2.1 mm × 100 mm, Waters) was used on a HILIC mode for the separation of the lipid classes. The mobile phase of solvent A (10 mM ammonium acetate in 95:5 acetonitrile/water) and solvent B (10 mM ammonium acetate in 50:50 acetonitrile/water) was at a flow rate of 0.6 ml/min. The UPLC elution gradient was 0.1-20.0% B for 2 min, then 20-80% B for 3 min followed by 3 min re-equilibration. The eluted lipids were directly introduced into the mass spectrometer with a desolvation temperature of 500 °C and a capillary voltage of 2.8 kV under positive ESI mode, and the source temperature was set at 120°C. The analytes were monitored under full-scan mode with mass ranging from m/z 100 to 600, combined with a daughter scan from m/z 50 to 650 for fragmentor of 638.6(m/z), with a collision energy of 20 V. An MRM transition for DAG (18:1-18:1) quantitative detection was set as 638.6 to &gt;339.3, with a core voltage of 50 V, and collision energy of 20 V Masslynx 4.0 was used to acquire and screen MS and MS/MS data. Notably, the available HPLC-MS results suggest markedly higher concentration of DAG molecule than purification buffer, but we cannot distinguish 1,2-DAG from its regioisomer 1,3-DAG with current available data. However, we found 1,2-DAG fits the electron density better, therefore, we modeled the electron density as 1,2-DAG molecule.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title> <p>The cDNAs of hTRPC5 were kindly provided by Dr. Xiaolin Zhang. We thank Dr. Yi Rao for sharing FLIPR instruments and Shangchen Han for technical supports. We thank the National Center for Protein Sciences at Peking University in Beijing, China, for assistance with negative stain EM. Cryo-EM data collection was supported by electron microscopy laboratory and Cryo-EM platform of Peking University with the assistance of Xuemei Li, Daqi Yu, Xia Pei, Bo Shao, Guopeng Wang, and Zhenxi Guo. Part of structural computation was also performed on the Computing Platform of the Center for Life Science and High-performance Computing Platform of Peking University. This work is supported by grants from the Ministry of Science and Technology of China (National Key R and D Program of China, 2016YFA0502004 to LC), National Natural Science Foundation of China (91957201, 31870833, and 31821091 to LC, 31900859 to J-X W), and the China Postdoctoral Science Foundation (2016M600856, 2017T100014, 2019M650324, and 2019T120014 to J-XW). J-XW is supported by the Boya Postdoctoral Fellowship of Peking University and the postdoctoral foundation of the Peking-Tsinghua Center for Life Sciences, Peking University (CLS).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-63429-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The density maps for hTRPC5 have been deposited to the Electron Microscopy Data Bank (EMDB) under the accession number: EMD-30987 for apo hTRPC5, EMD-30575 for CMZ-bound hTRPC5, and EMD-30576 for HC-070-bound hTRPC5. Coordinates of the atomic model have been deposited in the Protein Data Bank (PDB) under accession number 7E4T for apo hTRPC5, 7D4P for CMZ-bound hTRPC5 and 7D4Q for HC-070-bound hTRPC5.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>cryo-EM structure of hTRPC5 in complex with Clemizole</data-title><source>Electron Microscopy Data Bank</source><pub-id assigning-authority="EMDB" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-30575">EMD-30575</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>cryo-EM structure of hTRPC5 in complex with Clemizole</data-title><source>RCSB Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7D4P">7D4P</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>cryo-EM structure of hTRPC5 in complex with HC-070</data-title><source>Electron Microscopy Data Bank</source><pub-id assigning-authority="EMDB" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-30576">EMD-30576</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>cryo-EM structure of hTRPC5 in complex with HC-070</data-title><source>RCSB Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7D4Q">7D4Q</pub-id></element-citation></p><p><element-citation id="dataset5" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>cryo-EM structure of hTRPC5 in apo state</data-title><source>Electron Microscopy Data Bank</source><pub-id assigning-authority="EMDB" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-30987">EMD-30987</pub-id></element-citation></p><p><element-citation id="dataset6" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>cryo-EM structure of hTRPC5 in apo state</data-title><source>RCSB Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7E4T">7E4T</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation id="dataset7" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>JX</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Cryo-EM structure of human TRPC6 at 3.8A resolution</data-title><source>Electron Microscopy Data Bank</source><pub-id assigning-authority="EMDB" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-6856">EMD-6856</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>PD</given-names></name><name><surname>Afonine</surname> <given-names>PV</given-names></name><name><surname>Bunkóczi</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>VB</given-names></name><name><surname>Davis</surname> <given-names>IW</given-names></name><name><surname>Echols</surname> <given-names>N</given-names></name><name><surname>Headd</surname> <given-names>JJ</given-names></name><name><surname>Hung</surname> <given-names>LW</given-names></name><name><surname>Kapral</surname> <given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>McCoy</surname> <given-names>AJ</given-names></name><name><surname>Moriarty</surname> <given-names>NW</given-names></name><name><surname>Oeffner</surname> <given-names>R</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name><name><surname>Richardson</surname> <given-names>DC</given-names></name><name><surname>Richardson</surname> <given-names>JS</given-names></name><name><surname>Terwilliger</surname> <given-names>TC</given-names></name><name><surname>Zwart</surname> <given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbulut</surname> <given-names>Y</given-names></name><name><surname>Gaunt</surname> <given-names>HJ</given-names></name><name><surname>Muraki</surname> <given-names>K</given-names></name><name><surname>Ludlow</surname> <given-names>MJ</given-names></name><name><surname>Amer</surname> <given-names>MS</given-names></name><name><surname>Bruns</surname> <given-names>A</given-names></name><name><surname>Vasudev</surname> <given-names>NS</given-names></name><name><surname>Radtke</surname> <given-names>L</given-names></name><name><surname>Willot</surname> <given-names>M</given-names></name><name><surname>Hahn</surname> <given-names>S</given-names></name><name><surname>Seitz</surname> <given-names>T</given-names></name><name><surname>Ziegler</surname> <given-names>S</given-names></name><name><surname>Christmann</surname> <given-names>M</given-names></name><name><surname>Beech</surname> <given-names>DJ</given-names></name><name><surname>Waldmann</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>(-)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels</article-title><source>Angewandte Chemie International Edition</source><volume>54</volume><fpage>3787</fpage><lpage>3791</lpage><pub-id pub-id-type="doi">10.1002/anie.201411511</pub-id><pub-id pub-id-type="pmid">25707820</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asanov</surname> <given-names>A</given-names></name><name><surname>Sampieri</surname> <given-names>A</given-names></name><name><surname>Moreno</surname> <given-names>C</given-names></name><name><surname>Pacheco</surname> <given-names>J</given-names></name><name><surname>Salgado</surname> <given-names>A</given-names></name><name><surname>Sherry</surname> <given-names>R</given-names></name><name><surname>Vaca</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Combined single channel and single molecule detection identifies subunit composition of STIM1-activated transient receptor potential canonical (TRPC) channels</article-title><source>Cell Calcium</source><volume>57</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2014.10.011</pub-id><pub-id pub-id-type="pmid">25465892</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Autzen</surname> <given-names>HE</given-names></name><name><surname>Myasnikov</surname> <given-names>AG</given-names></name><name><surname>Campbell</surname> <given-names>MG</given-names></name><name><surname>Asarnow</surname> <given-names>D</given-names></name><name><surname>Julius</surname> <given-names>D</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of the human TRPM4 ion channel in a lipid nanodisc</article-title><source>Science</source><volume>359</volume><fpage>228</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1126/science.aar4510</pub-id><pub-id pub-id-type="pmid">29217581</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Horne</surname> <given-names>D</given-names></name><name><surname>White</surname> <given-names>R</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Lee</surname> <given-names>P</given-names></name><name><surname>Gu</surname> <given-names>Y</given-names></name><name><surname>Ghimire-Rijal</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>DC</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for pharmacological modulation of the TRPC6 channel</article-title><source>eLife</source><volume>9</volume><elocation-id>e53311</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.53311</pub-id><pub-id pub-id-type="pmid">32149605</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname> <given-names>A</given-names></name><name><surname>Speicher</surname> <given-names>T</given-names></name><name><surname>Stoerger</surname> <given-names>C</given-names></name><name><surname>Sell</surname> <given-names>T</given-names></name><name><surname>Dettmer</surname> <given-names>V</given-names></name><name><surname>Jusoh</surname> <given-names>SA</given-names></name><name><surname>Abdulmughni</surname> <given-names>A</given-names></name><name><surname>Cavalié</surname> <given-names>A</given-names></name><name><surname>Philipp</surname> <given-names>SE</given-names></name><name><surname>Zhu</surname> <given-names>MX</given-names></name><name><surname>Helms</surname> <given-names>V</given-names></name><name><surname>Wissenbach</surname> <given-names>U</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Conserved gating elements in TRPC4 and TRPC5 channels</article-title><source>Journal of Biological Chemistry</source><volume>288</volume><fpage>19471</fpage><lpage>19483</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.478305</pub-id><pub-id pub-id-type="pmid">23677990</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname> <given-names>NT</given-names></name><name><surname>Kaczmarek</surname> <given-names>JS</given-names></name><name><surname>Clapham</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Intracellular calcium strongly potentiates agonist-activated TRPC5 channels</article-title><source>Journal of General Physiology</source><volume>133</volume><fpage>525</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1085/jgp.200810153</pub-id><pub-id pub-id-type="pmid">19398778</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname> <given-names>E</given-names></name><name><surname>Liao</surname> <given-names>M</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name><name><surname>Julius</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TRPV1 structures in distinct conformations reveal activation mechanisms</article-title><source>Nature</source><volume>504</volume><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1038/nature12823</pub-id><pub-id pub-id-type="pmid">24305161</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname> <given-names>C</given-names></name><name><surname>Raman</surname> <given-names>P</given-names></name><name><surname>Tullai</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>L</given-names></name><name><surname>Henault</surname> <given-names>M</given-names></name><name><surname>Thomas</surname> <given-names>E</given-names></name><name><surname>Yeola</surname> <given-names>S</given-names></name><name><surname>Lao</surname> <given-names>J</given-names></name><name><surname>McPate</surname> <given-names>M</given-names></name><name><surname>Verkuyl</surname> <given-names>JM</given-names></name><name><surname>Marsh</surname> <given-names>G</given-names></name><name><surname>Sarber</surname> <given-names>J</given-names></name><name><surname>Amaral</surname> <given-names>A</given-names></name><name><surname>Bailey</surname> <given-names>S</given-names></name><name><surname>Lubicka</surname> <given-names>D</given-names></name><name><surname>Pham</surname> <given-names>H</given-names></name><name><surname>Miranda</surname> <given-names>N</given-names></name><name><surname>Ding</surname> <given-names>J</given-names></name><name><surname>Tang</surname> <given-names>HM</given-names></name><name><surname>Ju</surname> <given-names>H</given-names></name><name><surname>Tranter</surname> <given-names>P</given-names></name><name><surname>Ji</surname> <given-names>N</given-names></name><name><surname>Krastel</surname> <given-names>P</given-names></name><name><surname>Jain</surname> <given-names>RK</given-names></name><name><surname>Schumacher</surname> <given-names>AM</given-names></name><name><surname>Loureiro</surname> <given-names>JJ</given-names></name><name><surname>George</surname> <given-names>E</given-names></name><name><surname>Berellini</surname> <given-names>G</given-names></name><name><surname>Ross</surname> <given-names>NT</given-names></name><name><surname>Bushell</surname> <given-names>SM</given-names></name><name><surname>Erdemli</surname> <given-names>G</given-names></name><name><surname>Solomon</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Englerin A agonizes the TRPC4/C5 cation channels to inhibit tumor cell line proliferation</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0127498</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0127498</pub-id><pub-id pub-id-type="pmid">26098886</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>McMullan</surname> <given-names>G</given-names></name><name><surname>Faruqi</surname> <given-names>AR</given-names></name><name><surname>Murshudov</surname> <given-names>GN</given-names></name><name><surname>Short</surname> <given-names>JM</given-names></name><name><surname>Scheres</surname> <given-names>SH</given-names></name><name><surname>Henderson</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy</article-title><source>Ultramicroscopy</source><volume>135</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ultramic.2013.06.004</pub-id><pub-id pub-id-type="pmid">23872039</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname> <given-names>YH</given-names></name><name><surname>Sun Ahn</surname> <given-names>H</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Hoon Shin</surname> <given-names>D</given-names></name><name><surname>Su Kim</surname> <given-names>S</given-names></name><name><surname>Yong Kim</surname> <given-names>K</given-names></name><name><surname>Bok Lee</surname> <given-names>W</given-names></name><name><surname>Ik Cha</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Immunohistochemical study on the distribution of TRPC channels in the rat Hippocampus</article-title><source>Brain Research</source><volume>1085</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.02.087</pub-id><pub-id pub-id-type="pmid">16580647</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname> <given-names>YH</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Moon</surname> <given-names>NJ</given-names></name><name><surname>Oh</surname> <given-names>CS</given-names></name><name><surname>Lee</surname> <given-names>E</given-names></name><name><surname>Shin</surname> <given-names>DH</given-names></name><name><surname>Kim</surname> <given-names>SS</given-names></name><name><surname>Lee</surname> <given-names>WB</given-names></name><name><surname>Lee</surname> <given-names>JY</given-names></name><name><surname>Cha</surname> <given-names>CI</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Immunohistochemical study on the distribution of canonical transient receptor potential channels in rat basal ganglia</article-title><source>Neuroscience Letters</source><volume>422</volume><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2007.05.042</pub-id><pub-id pub-id-type="pmid">17590510</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clapham</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>TRP channels as cellular sensors</article-title><source>Nature</source><volume>426</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1038/nature02196</pub-id><pub-id pub-id-type="pmid">14654832</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diver</surname> <given-names>MM</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name><name><surname>Julius</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural insights into TRPM8 inhibition and desensitization</article-title><source>Science</source><volume>365</volume><fpage>1434</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1126/science.aax6672</pub-id><pub-id pub-id-type="pmid">31488702</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Zeng</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>GL</given-names></name><name><surname>Peng</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Clapham</surname> <given-names>DE</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of the mouse TRPC4 ion channel</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>3102</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05247-9</pub-id><pub-id pub-id-type="pmid">30082700</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>G-L</given-names></name><name><surname>Ge</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Xie</surname> <given-names>K</given-names></name><name><surname>Peng</surname> <given-names>X</given-names></name><name><surname>Zhou</surname> <given-names>W</given-names></name><name><surname>Zhong</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Xue</surname> <given-names>C</given-names></name><name><surname>Liang</surname> <given-names>B</given-names></name><name><surname>Zhu</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Tian</surname> <given-names>X-L</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Clapham</surname> <given-names>DE</given-names></name><name><surname>Zeng</surname> <given-names>B</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cryo-EM structure of TRPC5 at 2.8-Å resolution reveals unique and conserved structural elements essential for channel function</article-title><source>Science Advances</source><volume>5</volume><elocation-id>eaaw7935</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aaw7935</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>P</given-names></name><name><surname>Lohkamp</surname> <given-names>B</given-names></name><name><surname>Scott</surname> <given-names>WG</given-names></name><name><surname>Cowtan</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of coot</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Cao</surname> <given-names>E</given-names></name><name><surname>Julius</surname> <given-names>D</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action</article-title><source>Nature</source><volume>534</volume><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1038/nature17964</pub-id><pub-id pub-id-type="pmid">27281200</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname> <given-names>SA</given-names></name><name><surname>Guzmán</surname> <given-names>GA</given-names></name><name><surname>Wissenbach</surname> <given-names>U</given-names></name><name><surname>Philipp</surname> <given-names>SE</given-names></name><name><surname>Zhu</surname> <given-names>MX</given-names></name><name><surname>Bruns</surname> <given-names>D</given-names></name><name><surname>Cavalié</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>TRPC5 is a Ca2+-activated channel functionally coupled to Ca2+-selective ion channels</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>34423</fpage><lpage>34432</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.018192</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Winkler</surname> <given-names>PA</given-names></name><name><surname>Sun</surname> <given-names>W</given-names></name><name><surname>Lü</surname> <given-names>W</given-names></name><name><surname>Du</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Architecture of the TRPM2 channel and its activation mechanism by ADP-ribose and calcium</article-title><source>Nature</source><volume>562</volume><fpage>145</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0558-4</pub-id><pub-id pub-id-type="pmid">30250252</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname> <given-names>J-P</given-names></name><name><surname>Hong</surname> <given-names>C</given-names></name><name><surname>Park</surname> <given-names>EJ</given-names></name><name><surname>Jeon</surname> <given-names>J-H</given-names></name><name><surname>Cho</surname> <given-names>N-H</given-names></name><name><surname>Kim</surname> <given-names>I-G</given-names></name><name><surname>Choe</surname> <given-names>H</given-names></name><name><surname>Muallem</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>HJ</given-names></name><name><surname>So</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Selective gαi subunits as novel direct activators of transient receptor potential canonical (TRPC)4 and TRPC5 channels</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>17029</fpage><lpage>17039</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.326553</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Just</surname> <given-names>S</given-names></name><name><surname>Chenard</surname> <given-names>BL</given-names></name><name><surname>Ceci</surname> <given-names>A</given-names></name><name><surname>Strassmaier</surname> <given-names>T</given-names></name><name><surname>Chong</surname> <given-names>JA</given-names></name><name><surname>Blair</surname> <given-names>NT</given-names></name><name><surname>Gallaschun</surname> <given-names>RJ</given-names></name><name><surname>Del Camino</surname> <given-names>D</given-names></name><name><surname>Cantin</surname> <given-names>S</given-names></name><name><surname>D'Amours</surname> <given-names>M</given-names></name><name><surname>Eickmeier</surname> <given-names>C</given-names></name><name><surname>Fanger</surname> <given-names>CM</given-names></name><name><surname>Hecker</surname> <given-names>C</given-names></name><name><surname>Hessler</surname> <given-names>DP</given-names></name><name><surname>Hengerer</surname> <given-names>B</given-names></name><name><surname>Kroker</surname> <given-names>KS</given-names></name><name><surname>Malekiani</surname> <given-names>S</given-names></name><name><surname>Mihalek</surname> <given-names>R</given-names></name><name><surname>McLaughlin</surname> <given-names>J</given-names></name><name><surname>Rast</surname> <given-names>G</given-names></name><name><surname>Witek</surname> <given-names>J</given-names></name><name><surname>Sauer</surname> <given-names>A</given-names></name><name><surname>Pryce</surname> <given-names>CR</given-names></name><name><surname>Moran</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0191225</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0191225</pub-id><pub-id pub-id-type="pmid">29385160</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanki</surname> <given-names>H</given-names></name><name><surname>Kinoshita</surname> <given-names>M</given-names></name><name><surname>Akaike</surname> <given-names>A</given-names></name><name><surname>Satoh</surname> <given-names>M</given-names></name><name><surname>Mori</surname> <given-names>Y</given-names></name><name><surname>Kaneko</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Activation of inositol 1,4,5-trisphosphate receptor is essential for the opening of mouse TRP5 channels</article-title><source>Molecular Pharmacology</source><volume>60</volume><fpage>989</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1124/mol.60.5.989</pub-id><pub-id pub-id-type="pmid">11641427</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawate</surname> <given-names>T</given-names></name><name><surname>Gouaux</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins</article-title><source>Structure</source><volume>14</volume><fpage>673</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.str.2006.01.013</pub-id><pub-id pub-id-type="pmid">16615909</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Wu</surname> <given-names>JX</given-names></name><name><surname>Ding</surname> <given-names>D</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Gao</surname> <given-names>N</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structure of a pancreatic ATP-Sensitive potassium channel</article-title><source>Cell</source><volume>168</volume><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.12.028</pub-id><pub-id pub-id-type="pmid">28086082</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtenegger</surname> <given-names>M</given-names></name><name><surname>Tiapko</surname> <given-names>O</given-names></name><name><surname>Svobodova</surname> <given-names>B</given-names></name><name><surname>Stockner</surname> <given-names>T</given-names></name><name><surname>Glasnov</surname> <given-names>TN</given-names></name><name><surname>Schreibmayer</surname> <given-names>W</given-names></name><name><surname>Platzer</surname> <given-names>D</given-names></name><name><surname>de la Cruz</surname> <given-names>GG</given-names></name><name><surname>Krenn</surname> <given-names>S</given-names></name><name><surname>Schober</surname> <given-names>R</given-names></name><name><surname>Shrestha</surname> <given-names>N</given-names></name><name><surname>Schindl</surname> <given-names>R</given-names></name><name><surname>Romanin</surname> <given-names>C</given-names></name><name><surname>Groschner</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An optically controlled probe identifies lipid-gating fenestrations within the TRPC3 channel</article-title><source>Nature Chemical Biology</source><volume>14</volume><fpage>396</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0015-6</pub-id><pub-id pub-id-type="pmid">29556099</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minard</surname> <given-names>A</given-names></name><name><surname>Bauer</surname> <given-names>C</given-names></name><name><surname>Wright</surname> <given-names>D</given-names></name><name><surname>Rubaiy</surname> <given-names>H</given-names></name><name><surname>Muraki</surname> <given-names>K</given-names></name><name><surname>Beech</surname> <given-names>D</given-names></name><name><surname>Bon</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Remarkable progress with Small-Molecule modulation of TRPC1/4/5 channels: implications for understanding the channels in health and disease</article-title><source>Cells</source><volume>7</volume><elocation-id>52</elocation-id><pub-id pub-id-type="doi">10.3390/cells7060052</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minard</surname> <given-names>A</given-names></name><name><surname>Bauer</surname> <given-names>CC</given-names></name><name><surname>Chuntharpursat-Bon</surname> <given-names>E</given-names></name><name><surname>Pickles</surname> <given-names>IB</given-names></name><name><surname>Wright</surname> <given-names>DJ</given-names></name><name><surname>Ludlow</surname> <given-names>MJ</given-names></name><name><surname>Burnham</surname> <given-names>MP</given-names></name><name><surname>Warriner</surname> <given-names>SL</given-names></name><name><surname>Beech</surname> <given-names>DJ</given-names></name><name><surname>Muraki</surname> <given-names>K</given-names></name><name><surname>Bon</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Potent, selective, and subunit-dependent activation of TRPC5 channels by a xanthine derivative</article-title><source>British Journal of Pharmacology</source><volume>176</volume><fpage>3924</fpage><lpage>3938</lpage><pub-id pub-id-type="doi">10.1111/bph.14791</pub-id><pub-id pub-id-type="pmid">31277085</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazono</surname> <given-names>K</given-names></name><name><surname>Tabei</surname> <given-names>N</given-names></name><name><surname>Morita</surname> <given-names>S</given-names></name><name><surname>Ohnishi</surname> <given-names>Y</given-names></name><name><surname>Horinouchi</surname> <given-names>S</given-names></name><name><surname>Tanokura</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Substrate recognition mechanism and substrate-dependent conformational changes of an ROK family glucokinase from Streptomyces griseus</article-title><source>Journal of Bacteriology</source><volume>194</volume><fpage>607</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1128/JB.06173-11</pub-id><pub-id pub-id-type="pmid">22101842</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montell</surname> <given-names>C</given-names></name><name><surname>Birnbaumer</surname> <given-names>L</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name><name><surname>Bindels</surname> <given-names>RJ</given-names></name><name><surname>Bruford</surname> <given-names>EA</given-names></name><name><surname>Caterina</surname> <given-names>MJ</given-names></name><name><surname>Clapham</surname> <given-names>DE</given-names></name><name><surname>Harteneck</surname> <given-names>C</given-names></name><name><surname>Heller</surname> <given-names>S</given-names></name><name><surname>Julius</surname> <given-names>D</given-names></name><name><surname>Kojima</surname> <given-names>I</given-names></name><name><surname>Mori</surname> <given-names>Y</given-names></name><name><surname>Penner</surname> <given-names>R</given-names></name><name><surname>Prawitt</surname> <given-names>D</given-names></name><name><surname>Scharenberg</surname> <given-names>AM</given-names></name><name><surname>Schultz</surname> <given-names>G</given-names></name><name><surname>Shimizu</surname> <given-names>N</given-names></name><name><surname>Zhu</surname> <given-names>MX</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A unified nomenclature for the superfamily of TRP cation channels</article-title><source>Molecular Cell</source><volume>9</volume><fpage>229</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00448-3</pub-id><pub-id pub-id-type="pmid">11864597</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montell</surname> <given-names>C</given-names></name><name><surname>Rubin</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Molecular characterization of the <italic>Drosophila</italic> trp locus: a putative integral membrane protein required for phototransduction</article-title><source>Neuron</source><volume>2</volume><fpage>1313</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(89)90069-X</pub-id><pub-id pub-id-type="pmid">2516726</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriarty</surname> <given-names>NW</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>Adams</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Electronic ligand builder and optimization workbench (eLBOW): a tool for ligand coordinate and restraint generation</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>65</volume><fpage>1074</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1107/S0907444909029436</pub-id><pub-id pub-id-type="pmid">19770504</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ordaz</surname> <given-names>B</given-names></name><name><surname>Tang</surname> <given-names>J</given-names></name><name><surname>Xiao</surname> <given-names>R</given-names></name><name><surname>Salgado</surname> <given-names>A</given-names></name><name><surname>Sampieri</surname> <given-names>A</given-names></name><name><surname>Zhu</surname> <given-names>MX</given-names></name><name><surname>Vaca</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Calmodulin and calcium interplay in the modulation of TRPC5 channel activity: identification of a novel C-terminal domain for calcium/calmodulin-mediated facilitation</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>30788</fpage><lpage>30796</lpage><pub-id pub-id-type="doi">10.1074/jbc.M504745200</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname> <given-names>EF</given-names></name><name><surname>Goddard</surname> <given-names>TD</given-names></name><name><surname>Huang</surname> <given-names>CC</given-names></name><name><surname>Couch</surname> <given-names>GS</given-names></name><name><surname>Greenblatt</surname> <given-names>DM</given-names></name><name><surname>Meng</surname> <given-names>EC</given-names></name><name><surname>Ferrin</surname> <given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philipp</surname> <given-names>S</given-names></name><name><surname>Hambrecht</surname> <given-names>J</given-names></name><name><surname>Braslavski</surname> <given-names>L</given-names></name><name><surname>Schroth</surname> <given-names>G</given-names></name><name><surname>Freichel</surname> <given-names>M</given-names></name><name><surname>Murakami</surname> <given-names>M</given-names></name><name><surname>Cavalié</surname> <given-names>A</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A novel capacitative calcium entry channel expressed in excitable cells</article-title><source>The EMBO Journal</source><volume>17</volume><fpage>4274</fpage><lpage>4282</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.15.4274</pub-id><pub-id pub-id-type="pmid">9687496</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phulera</surname> <given-names>S</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Claxton</surname> <given-names>DP</given-names></name><name><surname>Yoder</surname> <given-names>N</given-names></name><name><surname>Yoshioka</surname> <given-names>C</given-names></name><name><surname>Gouaux</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cryo-EM structure of the benzodiazepine-sensitive α1β1γ2s tri-heteromeric GAB<sub>AA</sub> receptor in complex with GAB<sub>A</sub></article-title><source>eLife</source><volume>7</volume><elocation-id>e39383</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.39383</pub-id><pub-id pub-id-type="pmid">30044221</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname> <given-names>A</given-names></name><name><surname>Rubinstein</surname> <given-names>JL</given-names></name><name><surname>Fleet</surname> <given-names>DJ</given-names></name><name><surname>Brubaker</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination</article-title><source>Nature Methods</source><volume>14</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4169</pub-id><pub-id pub-id-type="pmid">28165473</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riccio</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Moon</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>KS</given-names></name><name><surname>Smith</surname> <given-names>KS</given-names></name><name><surname>Rudolph</surname> <given-names>U</given-names></name><name><surname>Gapon</surname> <given-names>S</given-names></name><name><surname>Yao</surname> <given-names>GL</given-names></name><name><surname>Tsvetkov</surname> <given-names>E</given-names></name><name><surname>Rodig</surname> <given-names>SJ</given-names></name><name><surname>Van't Veer</surname> <given-names>A</given-names></name><name><surname>Meloni</surname> <given-names>EG</given-names></name><name><surname>Carlezon</surname> <given-names>WA</given-names></name><name><surname>Bolshakov</surname> <given-names>VY</given-names></name><name><surname>Clapham</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Essential role for TRPC5 in amygdala function and fear-related behavior</article-title><source>Cell</source><volume>137</volume><fpage>761</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.03.039</pub-id><pub-id pub-id-type="pmid">19450521</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname> <given-names>JM</given-names></name><name><surname>Schaefer</surname> <given-names>M</given-names></name><name><surname>Hill</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clemizole hydrochloride is a novel and potent inhibitor of transient receptor potential channel TRPC5</article-title><source>Molecular Pharmacology</source><volume>86</volume><fpage>514</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1124/mol.114.093229</pub-id><pub-id pub-id-type="pmid">25140002</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname> <given-names>M</given-names></name><name><surname>Plant</surname> <given-names>TD</given-names></name><name><surname>Obukhov</surname> <given-names>AG</given-names></name><name><surname>Hofmann</surname> <given-names>T</given-names></name><name><surname>Gudermann</surname> <given-names>T</given-names></name><name><surname>Schultz</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Receptor-mediated regulation of the nonselective cation channels TRPC4 and TRPC5</article-title><source>Journal of Biological Chemistry</source><volume>275</volume><fpage>17517</fpage><lpage>17526</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.23.17517</pub-id><pub-id pub-id-type="pmid">10837492</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaldecker</surname> <given-names>T</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Tarabanis</surname> <given-names>C</given-names></name><name><surname>Tian</surname> <given-names>D</given-names></name><name><surname>Hakroush</surname> <given-names>S</given-names></name><name><surname>Castonguay</surname> <given-names>P</given-names></name><name><surname>Ahn</surname> <given-names>W</given-names></name><name><surname>Wallentin</surname> <given-names>H</given-names></name><name><surname>Heid</surname> <given-names>H</given-names></name><name><surname>Hopkins</surname> <given-names>CR</given-names></name><name><surname>Lindsley</surname> <given-names>CW</given-names></name><name><surname>Riccio</surname> <given-names>A</given-names></name><name><surname>Buvall</surname> <given-names>L</given-names></name><name><surname>Weins</surname> <given-names>A</given-names></name><name><surname>Greka</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inhibition of the TRPC5 ion channel protects the kidney filter</article-title><source>Journal of Clinical Investigation</source><volume>123</volume><fpage>5298</fpage><lpage>5309</lpage><pub-id pub-id-type="doi">10.1172/JCI71165</pub-id><pub-id pub-id-type="pmid">24231357</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>S</given-names></name><name><surname>Hopkins</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Review of transient receptor potential canonical (TRPC5) Channel modulators and diseases</article-title><source>Journal of Medicinal Chemistry</source><volume>62</volume><fpage>7589</fpage><lpage>7602</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01954</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>AK</given-names></name><name><surname>Saotome</surname> <given-names>K</given-names></name><name><surname>McGoldrick</surname> <given-names>LL</given-names></name><name><surname>Sobolevsky</surname> <given-names>AI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural bases of TRP channel TRPV6 allosteric modulation by 2-APB</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2465</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04828-y</pub-id><pub-id pub-id-type="pmid">29941865</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smart</surname> <given-names>OS</given-names></name><name><surname>Neduvelil</surname> <given-names>JG</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Wallace</surname> <given-names>BA</given-names></name><name><surname>Sansom</surname> <given-names>MSP</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>HOLE: a program for the analysis of the pore dimensions of ion channel structural models</article-title><source>Journal of Molecular Graphics</source><volume>14</volume><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/S0263-7855(97)00009-X</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sossey-Alaoui</surname> <given-names>K</given-names></name><name><surname>Lyon</surname> <given-names>JA</given-names></name><name><surname>Jones</surname> <given-names>L</given-names></name><name><surname>Abidi</surname> <given-names>FE</given-names></name><name><surname>Hartung</surname> <given-names>AJ</given-names></name><name><surname>Hane</surname> <given-names>B</given-names></name><name><surname>Schwartz</surname> <given-names>CE</given-names></name><name><surname>Stevenson</surname> <given-names>RE</given-names></name><name><surname>Srivastava</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Molecular cloning and characterization of TRPC5 (HTRP5), the human homologue of a mouse brain receptor-activated capacitative Ca2+ entry channel</article-title><source>Genomics</source><volume>60</volume><fpage>330</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1006/geno.1999.5924</pub-id><pub-id pub-id-type="pmid">10493832</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storch</surname> <given-names>U</given-names></name><name><surname>Forst</surname> <given-names>AL</given-names></name><name><surname>Pardatscher</surname> <given-names>F</given-names></name><name><surname>Erdogmus</surname> <given-names>S</given-names></name><name><surname>Philipp</surname> <given-names>M</given-names></name><name><surname>Gregoritza</surname> <given-names>M</given-names></name><name><surname>Mederos Y Schnitzler</surname> <given-names>M</given-names></name><name><surname>Gudermann</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dynamic NHERF interaction with TRPC4/5 proteins is required for channel gating by diacylglycerol</article-title><source>PNAS</source><volume>114</volume><fpage>E37</fpage><lpage>E46</lpage><pub-id pub-id-type="doi">10.1073/pnas.1612263114</pub-id><pub-id pub-id-type="pmid">27994151</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svobodova</surname> <given-names>B</given-names></name><name><surname>Lichtenegger</surname> <given-names>M</given-names></name><name><surname>Platzer</surname> <given-names>D</given-names></name><name><surname>Di Giuro</surname> <given-names>CML</given-names></name><name><surname>de la Cruz</surname> <given-names>GG</given-names></name><name><surname>Glasnov</surname> <given-names>T</given-names></name><name><surname>Schreibmayer</surname> <given-names>W</given-names></name><name><surname>Groschner</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A single point mutation in the TRPC3 lipid-recognition window generates supersensitivity to benzimidazole channel activators</article-title><source>Cell Calcium</source><volume>79</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2019.02.007</pub-id><pub-id pub-id-type="pmid">30798155</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Q</given-names></name><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Zheng</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>JX</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of the receptor-activated human TRPC6 and TRPC3 ion channels</article-title><source>Cell Research</source><volume>28</volume><fpage>746</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1038/s41422-018-0038-2</pub-id><pub-id pub-id-type="pmid">29700422</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlén</surname> <given-names>M</given-names></name><name><surname>Fagerberg</surname> <given-names>L</given-names></name><name><surname>Hallström</surname> <given-names>BM</given-names></name><name><surname>Lindskog</surname> <given-names>C</given-names></name><name><surname>Oksvold</surname> <given-names>P</given-names></name><name><surname>Mardinoglu</surname> <given-names>A</given-names></name><name><surname>Sivertsson</surname> <given-names>Å</given-names></name><name><surname>Kampf</surname> <given-names>C</given-names></name><name><surname>Sjöstedt</surname> <given-names>E</given-names></name><name><surname>Asplund</surname> <given-names>A</given-names></name><name><surname>Olsson</surname> <given-names>I</given-names></name><name><surname>Edlund</surname> <given-names>K</given-names></name><name><surname>Lundberg</surname> <given-names>E</given-names></name><name><surname>Navani</surname> <given-names>S</given-names></name><name><surname>Szigyarto</surname> <given-names>CA</given-names></name><name><surname>Odeberg</surname> <given-names>J</given-names></name><name><surname>Djureinovic</surname> <given-names>D</given-names></name><name><surname>Takanen</surname> <given-names>JO</given-names></name><name><surname>Hober</surname> <given-names>S</given-names></name><name><surname>Alm</surname> <given-names>T</given-names></name><name><surname>Edqvist</surname> <given-names>PH</given-names></name><name><surname>Berling</surname> <given-names>H</given-names></name><name><surname>Tegel</surname> <given-names>H</given-names></name><name><surname>Mulder</surname> <given-names>J</given-names></name><name><surname>Rockberg</surname> <given-names>J</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Schwenk</surname> <given-names>JM</given-names></name><name><surname>Hamsten</surname> <given-names>M</given-names></name><name><surname>von Feilitzen</surname> <given-names>K</given-names></name><name><surname>Forsberg</surname> <given-names>M</given-names></name><name><surname>Persson</surname> <given-names>L</given-names></name><name><surname>Johansson</surname> <given-names>F</given-names></name><name><surname>Zwahlen</surname> <given-names>M</given-names></name><name><surname>von Heijne</surname> <given-names>G</given-names></name><name><surname>Nielsen</surname> <given-names>J</given-names></name><name><surname>Pontén</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Proteomics Tissue-based map of the human proteome</article-title><source>Science</source><volume>347</volume><elocation-id>1260419</elocation-id><pub-id pub-id-type="doi">10.1126/science.1260419</pub-id><pub-id pub-id-type="pmid">25613900</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinayagam</surname> <given-names>D</given-names></name><name><surname>Quentin</surname> <given-names>D</given-names></name><name><surname>Yu-Strzelczyk</surname> <given-names>J</given-names></name><name><surname>Sitsel</surname> <given-names>O</given-names></name><name><surname>Merino</surname> <given-names>F</given-names></name><name><surname>Stabrin</surname> <given-names>M</given-names></name><name><surname>Hofnagel</surname> <given-names>O</given-names></name><name><surname>Yu</surname> <given-names>M</given-names></name><name><surname>Ledeboer</surname> <given-names>MW</given-names></name><name><surname>Nagel</surname> <given-names>G</given-names></name><name><surname>Malojcic</surname> <given-names>G</given-names></name><name><surname>Raunser</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis of TRPC4 regulation by calmodulin and pharmacological agents</article-title><source>eLife</source><volume>9</volume><elocation-id>e60603</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.60603</pub-id><pub-id pub-id-type="pmid">33236980</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Cheng</surname> <given-names>X</given-names></name><name><surname>Tian</surname> <given-names>J</given-names></name><name><surname>Xiao</surname> <given-names>Y</given-names></name><name><surname>Tian</surname> <given-names>T</given-names></name><name><surname>Xu</surname> <given-names>F</given-names></name><name><surname>Hong</surname> <given-names>X</given-names></name><name><surname>Zhu</surname> <given-names>MX</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TRPC channels: structure, function, regulation and recent advances in small molecular probes</article-title><source>Pharmacology &amp; Therapeutics</source><volume>209</volume><elocation-id>107497</elocation-id><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107497</pub-id><pub-id pub-id-type="pmid">32004513</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname> <given-names>DJ</given-names></name><name><surname>Simmons</surname> <given-names>KJ</given-names></name><name><surname>Johnson</surname> <given-names>RM</given-names></name><name><surname>Beech</surname> <given-names>DJ</given-names></name><name><surname>Muench</surname> <given-names>SP</given-names></name><name><surname>Bon</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human TRPC5 structures reveal interaction of a xanthine-based TRPC1/4/5 inhibitor with a conserved lipid binding site</article-title><source>Communications Biology</source><volume>3</volume><elocation-id>704</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-020-01437-8</pub-id><pub-id pub-id-type="pmid">33230284</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wulff</surname> <given-names>H</given-names></name><name><surname>Christophersen</surname> <given-names>P</given-names></name><name><surname>Colussi</surname> <given-names>P</given-names></name><name><surname>Chandy</surname> <given-names>KG</given-names></name><name><surname>Yarov-Yarovoy</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Antibodies and venom peptides: new modalities for ion channels</article-title><source>Nature Reviews Drug Discovery</source><volume>18</volume><fpage>339</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0013-8</pub-id><pub-id pub-id-type="pmid">30728472</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>SZ</given-names></name><name><surname>Sukumar</surname> <given-names>P</given-names></name><name><surname>Zeng</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Jairaman</surname> <given-names>A</given-names></name><name><surname>English</surname> <given-names>A</given-names></name><name><surname>Naylor</surname> <given-names>J</given-names></name><name><surname>Ciurtin</surname> <given-names>C</given-names></name><name><surname>Majeed</surname> <given-names>Y</given-names></name><name><surname>Milligan</surname> <given-names>CJ</given-names></name><name><surname>Bahnasi</surname> <given-names>YM</given-names></name><name><surname>Al-Shawaf</surname> <given-names>E</given-names></name><name><surname>Porter</surname> <given-names>KE</given-names></name><name><surname>Jiang</surname> <given-names>LH</given-names></name><name><surname>Emery</surname> <given-names>P</given-names></name><name><surname>Sivaprasadarao</surname> <given-names>A</given-names></name><name><surname>Beech</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TRPC channel activation by extracellular thioredoxin</article-title><source>Nature</source><volume>451</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/nature06414</pub-id><pub-id pub-id-type="pmid">18172497</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>LP</given-names></name><name><surname>Jiang</surname> <given-names>FJ</given-names></name><name><surname>Wu</surname> <given-names>GS</given-names></name><name><surname>Deng</surname> <given-names>K</given-names></name><name><surname>Wen</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Hong</surname> <given-names>X</given-names></name><name><surname>Zhu</surname> <given-names>MX</given-names></name><name><surname>Luo</surname> <given-names>HR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Acute treatment with a novel TRPC4/C5 channel inhibitor produces antidepressant and Anxiolytic-Like effects in mice</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0136255</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0136255</pub-id><pub-id pub-id-type="pmid">26317356</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname> <given-names>Y</given-names></name><name><surname>Le</surname> <given-names>SC</given-names></name><name><surname>Hsu</surname> <given-names>AL</given-names></name><name><surname>Borgnia</surname> <given-names>MJ</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Lee</surname> <given-names>SY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis of cooling agent and lipid sensing by the cold-activated TRPM8 channel</article-title><source>Science</source><volume>363</volume><elocation-id>eaav9334</elocation-id><pub-id pub-id-type="doi">10.1126/science.aav9334</pub-id><pub-id pub-id-type="pmid">30733385</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname> <given-names>F</given-names></name><name><surname>Xu</surname> <given-names>SZ</given-names></name><name><surname>Jackson</surname> <given-names>PK</given-names></name><name><surname>McHugh</surname> <given-names>D</given-names></name><name><surname>Kumar</surname> <given-names>B</given-names></name><name><surname>Fountain</surname> <given-names>SJ</given-names></name><name><surname>Beech</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Human TRPC5 channel activated by a multiplicity of signals in a single cell</article-title><source>The Journal of Physiology</source><volume>559</volume><fpage>739</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2004.065391</pub-id><pub-id pub-id-type="pmid">15254149</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Gctf: real-time CTF determination and correction</article-title><source>Journal of Structural Biology</source><volume>193</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2015.11.003</pub-id><pub-id pub-id-type="pmid">26592709</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>SQ</given-names></name><name><surname>Palovcak</surname> <given-names>E</given-names></name><name><surname>Armache</surname> <given-names>JP</given-names></name><name><surname>Verba</surname> <given-names>KA</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name><name><surname>Agard</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy</article-title><source>Nature Methods</source><volume>14</volume><fpage>331</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4193</pub-id><pub-id pub-id-type="pmid">28250466</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Castonguay</surname> <given-names>P</given-names></name><name><surname>Sidhom</surname> <given-names>EH</given-names></name><name><surname>Clark</surname> <given-names>AR</given-names></name><name><surname>Dvela-Levitt</surname> <given-names>M</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Sieber</surname> <given-names>J</given-names></name><name><surname>Wieder</surname> <given-names>N</given-names></name><name><surname>Jung</surname> <given-names>JY</given-names></name><name><surname>Andreeva</surname> <given-names>S</given-names></name><name><surname>Reichardt</surname> <given-names>J</given-names></name><name><surname>Dubois</surname> <given-names>F</given-names></name><name><surname>Hoffmann</surname> <given-names>SC</given-names></name><name><surname>Basgen</surname> <given-names>JM</given-names></name><name><surname>Montesinos</surname> <given-names>MS</given-names></name><name><surname>Weins</surname> <given-names>A</given-names></name><name><surname>Johnson</surname> <given-names>AC</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Garrett</surname> <given-names>MR</given-names></name><name><surname>Hopkins</surname> <given-names>CR</given-names></name><name><surname>Greka</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models</article-title><source>Science</source><volume>358</volume><fpage>1332</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1126/science.aal4178</pub-id><pub-id pub-id-type="pmid">29217578</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Qu</surname> <given-names>C</given-names></name><name><surname>Miller</surname> <given-names>M</given-names></name><name><surname>Tian</surname> <given-names>J</given-names></name><name><surname>Thakur</surname> <given-names>DP</given-names></name><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Deng</surname> <given-names>Z</given-names></name><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Wu</surname> <given-names>M</given-names></name><name><surname>McManus</surname> <given-names>OB</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Hong</surname> <given-names>X</given-names></name><name><surname>Zhu</surname> <given-names>MX</given-names></name><name><surname>Luo</surname> <given-names>HR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Identification and optimization of 2-aminobenzimidazole derivatives as novel inhibitors of TRPC4 and TRPC5 channels</article-title><source>British Journal of Pharmacology</source><volume>172</volume><fpage>3495</fpage><lpage>3509</lpage><pub-id pub-id-type="doi">10.1111/bph.13140</pub-id><pub-id pub-id-type="pmid">25816897</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zivanov</surname> <given-names>J</given-names></name><name><surname>Nakane</surname> <given-names>T</given-names></name><name><surname>Forsberg</surname> <given-names>BO</given-names></name><name><surname>Kimanius</surname> <given-names>D</given-names></name><name><surname>Hagen</surname> <given-names>WJ</given-names></name><name><surname>Lindahl</surname> <given-names>E</given-names></name><name><surname>Scheres</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>New tools for automated high-resolution cryo-EM structure determination in RELION-3</article-title><source>eLife</source><volume>7</volume><elocation-id>e42166</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.42166</pub-id><pub-id pub-id-type="pmid">30412051</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63429.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Stockbridge</surname><given-names>Randy B</given-names></name><role>Reviewing Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Stockbridge</surname><given-names>Randy B</given-names></name><role>Reviewer</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Cao</surname><given-names>Erhu</given-names> </name><role>Reviewer</role><aff><institution>University of Utah</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The TRPC5 channels are pharmaceutical targets for diverse pathologies, including anxiety, depression and kidney disease. The current manuscript presents structures of the human TRPC5 channel in complex with two different, mechanistically distinct inhibitors, clemizole and HC-070. The structural work in this manuscript is well-executed, with high quality maps and clear density for the inhibitors. Structural observations are coupled with extensive mutagenesis experiments to dissect the contributions of binding site residues to channel inhibition and to identify the molecular determinants of inhibitor selectivity for TRPC5 over closely related TRP channels. This work provides important mechanistic insight into the pharmaceutical modulation of TRPC5.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Structural basis for human TRPC5 channel inhibition by two distinct inhibitors&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, including Randy B Stockbridge as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Erhu Cao (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>In this article Song et al. present structures of the human TRPC5 channel in complex with inhibitors clemizole and HC-070 at 2.7 Å resolution. The authors identify the inhibitor binding sites and conduct site-directed mutagenesis studies in order to dissect the contribution of binding site residues to channel inhibition and to identify the molecular determinants of inhibitor selectivity for TRPC5 vs. TRPC3/6/7.</p><p>The structural work in this manuscript is generally well-executed, with high quality maps and clear density for the drugs. The authors perform extensive mutagenesis to identify positions that alter the IC<sub>50</sub> of the drugs. However, the reviewers were disappointed that in many cases, intriguing findings were not followed up with experiments or analysis to lead to mechanistic insights. In addition, the drug binding sites are in regions of the protein that are more generally involved in channel gating. Thus, basic electrophysiological characterization of the mutants with altered IC<sub>50</sub>s is an important control to establish whether the effects of these mutations are, in fact, primarily on the affinity of inhibitor binding.</p><p>Essential revisions:</p><p>1) It is essential to understand whether the mutants that alter inhibition also affect channel function. This would be an important control, as mutating the residues could result in a shift in gating kinetics and/or surface expression that might be reflected as a change in IC<sub>50</sub>. For example, in the Discussion, the authors point out that residues from inhibitor binding pocket B contribute to channel gating. This underscores the importance of characterizing the mutant behavior to distinguish the effects of mutations on gating kinetics vs. inhibitor binding. In addition, Duan et al., 2019, found that mutations to residue F576 altered channel function. The authors mutate a number of residues in this region (L572, Q573, F576…) and find shifts in IC<sub>50</sub> compared with wild type. However, without electrophysiological characterization of these mutants it is difficult to pin the shift in IC<sub>50</sub> to a change in affinity for the inhibitor alone.</p><p>2) Likewise, it is important to understand whether intracellular Ca<sup>2+</sup> is required for DMZ inhibition of TRPC5 since Icilin activates TRPM8 in a Ca<sup>2+</sup>-dependent manner and binds to a topologically equivalent site as CMZ.</p><p>3) It's not clear why the dose-response curves are plateau at values higher than 100%. In addition, from the Materials and methods, it looks like the Hill coefficient was allowed to vary in fitting the does response curves. Fits will improve if the number of parameters are increased, but if there is no mechanistic rationale, then this should not be done.</p><p>4) A number of interesting structural observations are made, but not translated into mechanistic insight. For example, N443, L496, and S495 do not appear to directly interact with CLZ, but affect the IC<sub>50</sub>. For the mutant L528A, HC-070 activates the channel in a dose-dependent manner. What is the mechanistic insight to be gained from these observations? The Zn2+ binding site is an important structural finding. Understanding its role in channel regulation would strengthen this manuscript.</p><p>5) Comparison to the apo mTRPC5 structure are made, but (as the authors acknowledge) hard to interpret since the homologue and membrane mimetic are different. It is not clear that the subtle changes shown in Figure 5 will affect the pore configuration. If it is technically feasible, the authors should solve a structure of apo hTRP5 in the same membrane mimetic as the drug-bound structures to allow for a direct comparison.</p><p>6) The resolution of the two maps is excellent but the atomic models could be improved. The clash score for both is rather high and both models contain a rather high number of poor rotamers. This should be an easy fix given the high resolution of the maps.</p><p>7) This manuscript would be more useful to the field if the Discussion was restructured to make a more detailed comparison with the many TRPC inhibitor bound structures (and published functional data). Such a Discussion would enhance the mechanistic insights that could be taken from these structures.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63429.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) It is essential to understand whether the mutants that alter inhibition also affect channel function. This would be an important control, as mutating the residues could result in a shift in gating kinetics and/or surface expression that might be reflected as a change in IC<sub>50</sub>. For example, in the Discussion, the authors point out that residues from inhibitor binding pocket B contribute to channel gating. This underscores the importance of characterizing the mutant behavior to distinguish the effects of mutations on gating kinetics vs. inhibitor binding. In addition, Duan et al., 2019, found that mutations to residue F576 altered channel function. The authors mutate a number of residues in this region (L572, Q573, F576…) and find shifts in IC50 compared with wild type. However, without electrophysiological characterization of these mutants it is difficult to pin the shift in IC<sub>50</sub> to a change in affinity for the inhibitor alone.</p></disp-quote><p>We fully agree with reviewers on that the shift in IC<sub>50</sub> is not sufficient to indicate the change in inhibitor affinity. We tried whole cell recordings for characterization of hTRPC5 mutants. Both EA and [Ca<sup>2+</sup>]<sub>o</sub> can activate wild-type hTRPC5. But Duan et al., 2019, found mutations in IBP-B abolished EA activation. Therefore, EA activation is not suitable to characterize hTRPC5 mutants at HC-070 binding sites (IBP-B). So we tried whole cell recording of hTRPC5 currents activated by [Ca<sup>2+</sup>]<sub>o</sub>, with 5 mM EDTA and 5 mM EGTA in pipette solution.</p><fig id="sa2fig1"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-resp-fig1-v2.tif"/></fig><p>In this condition, we found the wild-type hTRPC5 currents activated by [Ca<sup>2+</sup>]<sub>o</sub> had very slow kinetics which were different from cell to cell, suggesting this is not suitable for robust characterization of mutants either.Alternatively, we performed FLIPR experiments to measure the dose-response activation of hTRPC5 mutants by [Ca<sup>2+</sup>]<sub>o</sub> in Figure 2—figure supplement 2B-E. We have also determined the surface expression of these mutants in Figure 2—figure supplement 2F-G. These results collectively indicated that mutants showed robust surface expression and have similar trends of activation by [Ca<sup>2+</sup>]<sub>o</sub>. However, due to the unavailability of radioactive ligand binding assays, we cannot attribute the changes in IC<sub>50</sub> to the changes in inhibitor affinity. For explicitness, we have changed &quot;affinity&quot; into &quot;potency&quot; throughout the manuscript.</p><disp-quote content-type="editor-comment"><p>2) Likewise, it is important to understand whether intracellular Ca<sup>2+</sup> is required for DMZ inhibition of TRPC5 since Icilin activates TRPM8 in a Ca<sup>2+</sup>-dependent manner and binds to a topologically equivalent site as CMZ.</p></disp-quote><p>We have provided the electrophysiological data in Figure 4—figure supplement 1C. We used the whole cell mode with 1 mM EGTA/1 mM EDTA in pipette solution and 10 mM EGTA in bath solution to chelate calcium. We found pre-incubation of CMZ with the hTRPC5-expressing cell can inhibit the current evoked by EA, shown in revised Figure 4—figure supplement 1C, suggesting high intracellular Ca<sup>2+</sup> is not absolutely required for CMZ inhibition. We indicate this in the Results.</p><disp-quote content-type="editor-comment"><p>3) It's not clear why the dose-response curves are plateau at values higher than 100%. In addition, from the Materials and methods, it looks like the Hill coefficient was allowed to vary in fitting the does response curves. Fits will improve if the number of parameters are increased, but if there is no mechanistic rationale, then this should not be done.</p></disp-quote><p>We have determined the calcium activation levels of wild type hTRPC5 and mutants in Figure 2—figure supplement 2A, and removed the analysis of mutants with response less than 50% of wild type hTRPC5 due to low signal-to-noise ratio. Moreover, we have also re-analyzed the FLIPR data using the averaged base line as background and re-plotted all of the dose-response curves in normalization to wild type hTRPC5 (see revised Materials and methods section). For curve fitting, we found if we fixed the Hill coefficient to 1, the fitted curve would markedly deviates from experimental data points (<xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>).</p><fig id="sa2fig2"><label>Author response image 2.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63429-resp-fig2-v2.tif"/></fig><p>We reasoned that there is probably some cooperativity of inhibitor binding to four subunits of hTRPC5 channel, similar to what observed recently by others (PMID: 33230284). Therefore, we allowed Hill coefficient to change during curve fitting and provided the numbers obtained in revised Table 2 and Table 3.</p><disp-quote content-type="editor-comment"><p>4) A number of interesting structural observations are made, but not translated into mechanistic insight. For example, N443, L496, and S495 do not appear to directly interact with CLZ, but affect the IC<sub>50</sub>. For the mutant L528A, HC-070 activates the channel in a dose-dependent manner. What is the mechanistic insight to be gained from these observations? The Zn2+ binding site is an important structural finding. Understanding its role in channel regulation would strengthen this manuscript.</p></disp-quote><p>In Figure 2C-D, we have shown N443 is in close proximity to CMZ and probably has Van der Waals interactions with CMZ. Replacement of N443 with Leu might change these interactions. We have indicated this in the Results. L496A, L496M and L528A showed low signals (Figure 2—figure supplement 2A) and are not suitable for robust characterization and we have removed these mutants in the revised manuscript. We found the triple mutant C176A-C178A-C181A in zinc binding site retained reasonable surface expression and activation by both calcium and EA (Figure 2—figure supplement 2A, E-G). Therefore, we propose this zinc binding site might play other regulatory or structural roles, instead of ion channel gating, as indicated in the Results.</p><disp-quote content-type="editor-comment"><p>5) Comparison to the apo mTRPC5 structure are made, but (as the authors acknowledge) hard to interpret since the homologue and membrane mimetic are different. It is not clear that the subtle changes shown in Figure 5 will affect the pore configuration. If it is technically feasible, the authors should solve a structure of apo hTRP5 in the same membrane mimetic as the drug-bound structures to allow for a direct comparison.</p></disp-quote><p>We have provided the apo hTRPC5 structure in revised manuscript shown in Figure 1—figure supplements 2-3 for direct structural comparison in revised Figure 5.</p><disp-quote content-type="editor-comment"><p>6) The resolution of the two maps is excellent but the atomic models could be improved. The clash score for both is rather high and both models contain a rather high number of poor rotamers. This should be an easy fix given the high resolution of the maps.</p></disp-quote><p>We have further refined the structural model with new statistics shown in Table 1.</p><disp-quote content-type="editor-comment"><p>7) This manuscript would be more useful to the field if the Discussion was restructured to make a more detailed comparison with the many TRPC inhibitor bound structures (and published functional data). Such a Discussion would enhance the mechanistic insights that could be taken from these structures.</p></disp-quote><p>We have provided structural comparisons with new hTRPC4 and hTRPC5 inhibitor-bound structures in the Discussion and Figure 6—figure supplement 1.</p></body></sub-article></article>